<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31323913</article-id>
<article-id pub-id-type="pmc">6651166</article-id>
<article-id pub-id-type="doi">10.3390/ijms20133358</article-id>
<article-id pub-id-type="publisher-id">ijms-20-03358</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>High Functioning Autism with Missense Mutations in Synaptotagmin-Like Protein 4 (SYTL4) and Transmembrane Protein 187 (TMEM187) Genes: SYTL4- Protein Modeling, Protein-Protein Interaction, Expression Profiling and MicroRNA Studies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1797-1925</contrib-id>
<name>
<surname>Rafi</surname>
<given-names>Syed K.</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-03358">1</xref>
<xref ref-type="corresp" rid="c1-ijms-20-03358">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3306-9832</contrib-id>
<name>
<surname>Fernández-Jaén</surname>
<given-names>Alberto</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-03358">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Álvarez</surname>
<given-names>Sara</given-names>
</name>
<xref ref-type="aff" rid="af3-ijms-20-03358">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nadeau</surname>
<given-names>Owen W.</given-names>
</name>
<xref ref-type="aff" rid="af4-ijms-20-03358">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2911-0524</contrib-id>
<name>
<surname>Butler</surname>
<given-names>Merlin G.</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-03358">1</xref>
<xref ref-type="corresp" rid="c1-ijms-20-03358">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-03358"><label>1</label>Departments of Psychiatry &amp; Behavioral Sciences and Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160, USA</aff>
<aff id="af2-ijms-20-03358"><label>2</label>Department of Pediatric Neurology, Hospital Universitario Quirón, 28223 Madrid, Spain</aff>
<aff id="af3-ijms-20-03358"><label>3</label>Genomics and Medicine, NIM Genetics, 28108 Madrid, Spain</aff>
<aff id="af4-ijms-20-03358"><label>4</label>Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA</aff>
<author-notes>
<corresp id="c1-ijms-20-03358"><label>*</label>Correspondence: <email>rafigene@yahoo.com</email> (S.K.R.); <email>mbutler4@kumc.edu</email> (M.G.B.); Tel.: +816-787-4366 (S.K.R.); +913-588-1800 (M.G.B.)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>7</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>13</issue>
<elocation-id>3358</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>6</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>We describe a 7-year-old male with high functioning autism spectrum disorder (ASD) and maternally-inherited rare missense variant of Synaptotagmin-like protein 4 (<italic>SYTL4)</italic> gene (Xq22.1; c.835C&gt;T; p.Arg279Cys) and an unknown missense variant of Transmembrane protein 187 (<italic>TMEM187</italic>) gene (Xq28; c.708G&gt;T; p. Gln236His). Multiple in-silico predictions described in our study indicate a potentially damaging status for both X-linked genes. Analysis of predicted atomic threading models of the mutant and the native SYTL4 proteins suggest a potential structural change induced by the R279C variant which eliminates the stabilizing Arg279-Asp60 salt bridge in the N-terminal half of the SYTL4, affecting the functionality of the protein’s critical RAB-Binding Domain. In the European (Non-Finnish) population, the allele frequency for this variant is 0.00042. The <italic>SYTL4</italic> gene is known to directly interact with several members of the RAB family of genes, such as, <italic>RAB27A, RAB27B, RAB8A,</italic> and <italic>RAB3A</italic> which are known autism spectrum disorder genes. The <italic>SYTL4</italic> gene also directly interacts with three known autism genes: <italic>STX1A</italic>, <italic>SNAP25</italic> and <italic>STXBP1.</italic> Through a literature-based analytical approach, we identified three of five (60%) autism-associated serum microRNAs (miRs) with high predictive power among the total of 298 mouse Sytl4 associated/predicted microRNA interactions. Five of 13 (38%) miRs were differentially expressed in serum from ASD individuals which were predicted to interact with the mouse equivalent <italic>Sytl</italic>4 gene. <italic>TMEM187</italic> gene, like <italic>SYTL4</italic>, is a protein-coding gene that belongs to a group of genes which host microRNA genes in their introns or exons. The novel Q236H amino acid variant in the TMEM187 in our patient is near the terminal end region of the protein which is represented by multiple sequence alignments and hidden Markov models, preventing comparative structural analysis of the variant harboring region. Like <italic>SYTL4</italic>, the <italic>TMEM187</italic> gene is expressed in the brain and interacts with four known ASD genes, namely, <italic>HCFC1; TMLHE; MECP2</italic>; and <italic>GPHN. TMM187</italic> is in linkage with <italic>MECP2</italic>, which is a well-known determinant of brain structure and size and is a well-known autism gene. Other members of the <italic>TMEM</italic> gene family, <italic>TMEM132E</italic> and <italic>TMEM132D</italic> genes are associated with bipolar and panic disorders, respectively, while <italic>TMEM231</italic> is a known syndromic autism gene. Together, <italic>TMEM187</italic> and <italic>SYTL4</italic> genes directly interact with recognized important ASD genes, and their mRNAs are found in extracellular vesicles in the nervous system and stimulate target cells to translate into active protein. Our evidence shows that both these genes should be considered as candidate genes for autism. Additional biological testing is warranted to further determine the pathogenicity of these gene variants in the causation of autism.</p>
</abstract>
<kwd-group>
<kwd>autism candidate genes</kwd>
<kwd>synaptotagmin-like protein 4 (<italic>SYTL4</italic>)</kwd>
<kwd>transmembrane protein 187 <italic>(TMEM187</italic>)</kwd>
<kwd>SYTL4-protein structure</kwd>
<kwd>STRING-protein-protein interaction</kwd>
<kwd>expression profile</kwd>
<kwd>microRNA- interactions</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-03358" sec-type="intro">
<title>1. Introduction</title>
<p>Whole exome sequencing (WES) and occasionally whole-genome sequencing (WGS) are increasingly used in clinical practice for diagnosis, medical intervention and prognosis [<xref ref-type="bibr" rid="B1-ijms-20-03358">1</xref>,<xref ref-type="bibr" rid="B2-ijms-20-03358">2</xref>,<xref ref-type="bibr" rid="B3-ijms-20-03358">3</xref>]. High heritability estimates and family studies have supported a definite role of genetics in autism spectrum disorder (ASD). In neurodevelopmental disorders, particularly ASD and intellectual disability have diagnostic rates using WES which fluctuates in part from differences in clinical features from one study to another with rates up to 50% [<xref ref-type="bibr" rid="B4-ijms-20-03358">4</xref>,<xref ref-type="bibr" rid="B5-ijms-20-03358">5</xref>,<xref ref-type="bibr" rid="B6-ijms-20-03358">6</xref>,<xref ref-type="bibr" rid="B7-ijms-20-03358">7</xref>]. We describe a 7-year-old male with high-functioning autism spectrum disorder presenting for genetic services and whole exome sequencing following a normal microarray analysis, and variants were found in two X-linked genes: <italic>SYTL4</italic> and <italic>TMEM187</italic>.</p>
<sec id="sec1dot1-ijms-20-03358">
<title>1.1. Synaptotagmin-Like Protein 4 (SYTL4) Gene</title>
<p><italic>SYTL4</italic> gene, also known as Granuphilin/SLP4, encodes a member of the synaptotagmin-like protein family. Members of this family are characterized by an N-terminal RAB27-binding domain and C-terminal tandem C2 domains (<xref ref-type="fig" rid="ijms-20-03358-f001">Figure 1</xref> and <xref ref-type="fig" rid="ijms-20-03358-f002">Figure 2</xref>). The first C2 domain binds phospholipids in a calcium-independent manner, whereas the second C2 domain does not (<uri xlink:href="http://omim.org/entry/300723">http://omim.org/entry/300723</uri>). The encoded protein binds to specific small RAB-GTPases involved in intracellular membrane trafficking. This protein binds to RAB27 and may be involved in inhibiting dense core vesicle exocytosis. Alternate splicing results in multiple transcript variants that encode the same protein.</p>
<p><italic>SYTL4</italic> gene is relevant in neuronal system development and implicated in neurological and psychological diseases [<xref ref-type="bibr" rid="B8-ijms-20-03358">8</xref>] (Entrez Gene ID # 94121 (Human); ID # 27359 (Mouse). This gene is highly expressed in the bed nucleus of the stria terminalis (BNTS) [<xref ref-type="bibr" rid="B9-ijms-20-03358">9</xref>], a brain region that regulates mood, motivation for social behavior and social attachment [<xref ref-type="bibr" rid="B10-ijms-20-03358">10</xref>]. <italic>SYTL4</italic> expression is down regulated in the dorsal raphe nucleus from patients with major depressive disorder [<xref ref-type="bibr" rid="B11-ijms-20-03358">11</xref>]. In a mouse model of anxiety, significant change in Sytl4 was observed among the altered protein networks in the brain proteome [<xref ref-type="bibr" rid="B12-ijms-20-03358">12</xref>].</p>
<p>Targeted Null/Knockout mutant <italic>Sytl4</italic> mammalian phenotypes for <italic>Sytl4</italic> showed abnormal behavior and neurological phenotype [<xref ref-type="bibr" rid="B13-ijms-20-03358">13</xref>,<xref ref-type="bibr" rid="B14-ijms-20-03358">14</xref>,<xref ref-type="bibr" rid="B15-ijms-20-03358">15</xref>]. This gene interacts directly with other known autism genes. Confirmatively, gene expression knock-out <italic>Sytl4</italic> mutant mouse includes abnormal behavior and neurological problems [<xref ref-type="bibr" rid="B13-ijms-20-03358">13</xref>,<xref ref-type="bibr" rid="B14-ijms-20-03358">14</xref>]. Diseases already associated with <italic>SYTL4</italic> include Epileptic Encephalopathy (early Infantile) and Branchiootic syndrome (<uri xlink:href="www.genecards.org/cgi-Fbin/carddisp.pl?gene=SYTL4&amp;keywords=sytl4">www.genecards.org/cgi-Fbin/carddisp.pl?gene= SYTL4&amp;keywords=sytl4</uri>). A missense mutation in <italic>SYTL4</italic> was also recently reported in a female with autism and non-skewed X-chromosome inactivation [<xref ref-type="bibr" rid="B16-ijms-20-03358">16</xref>].</p>
</sec>
<sec id="sec1dot2-ijms-20-03358">
<title>1.2. Transmembrane Protein 187 (TEM187) Gene</title>
<p>The second gene in our study, <italic>TMEM187</italic>, is additionally known as <italic>ITBA1/CXORF12/DXS9878E</italic>- gene and consists of two exons which encode a multi-pass membrane protein expressed in all regions of the brain (<uri xlink:href="www.genecards.org/cgi-bin/carddisp.pl?gene=TMEM187&amp;keywords=TMEM187">www.genecards.org/cgi-bin/carddisp.pl?gene=TMEM187&amp;keywords=TMEM187</uri>). This is a conserved gene that codes a 261-amino-acid protein with six transmembrane helical domains. Unlike <italic>SYTL4</italic>, not much is known about this gene, but it belongs to a group of genes which host microRNA genes in their introns or exons [<xref ref-type="bibr" rid="B17-ijms-20-03358">17</xref>]. One of this gene’s related phenotypes is schizophrenia (GWAS catalog for <italic>TMEM187</italic> gene: Gene relation via enhancers containing phenotype SNP: Enhancer ID: GH0XJ153980). The latest STRING- network of protein interactions for this gene reveals that it directly interacts with four known ASD genes, namely, <italic>HCFC1; TMLHE; MECP2</italic> and <italic>GPHN</italic>. (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
</sec>
</sec>
<sec id="sec2-ijms-20-03358" sec-type="results">
<title>2. Results</title>
<sec id="sec2dot1-ijms-20-03358">
<title>2.1. Genomic Study</title>
<p>Whole exome sequencing performed in trios revealed maternally inherited X-linked missense variants: c.835C&gt;T, p. Arg279Cys in the <italic>SYTL4</italic> gene and c.708G&gt;T; and p. Gln236His in the <italic>TMEM187</italic> gene. Research findings will be discussed that relate specifically to <italic>SYTL4</italic> and <italic>TMEM187</italic> gene variants seen in our patient and as emerging candidate genes for autism.</p>
</sec>
<sec id="sec2dot2-ijms-20-03358">
<title>2.2. Synaptotagmin-Like 4 (SYTL4) Gene</title>
<sec id="sec2dot2dot1-ijms-20-03358">
<title>2.2.1. Deleterious and Damaging Nature of the <italic>SYTL4</italic>- Variant</title>
<p>The maternally inherited variant in Synaptotagmin-like protein 4 gene <italic>(SYTL4</italic>) at chromosome-X position g.99944930G&gt;A, c.835C&gt;T, p. Arg279Cys [NM_001174068.1] sits within exon 9 of the <italic>SYTL4</italic> gene located at the Xq22.1 cytoband (<xref ref-type="fig" rid="ijms-20-03358-f001">Figure 1</xref>). This particular <italic>SYTL4</italic> nucleotide variant CGC⇒TGC at position 835 (exon 9; alternating) has been predicted by large-scale genomic sequencing studies, such as the 1000 Genome project, to be deleterious (SIFT score 0.01) and possibly damaging (Polyphen score 0.79), which is further validated with a MAF score of 0.0005/2. The Exome Aggregation Consortium (ExAC) database including data from 1000 genomes further indicated that the <italic>SYTL4</italic> variant is also damaging.</p>
<p>Our patient is from Spain and according to Exome Aggregation Consortium, the allele frequency among European (Non-Finnish) population for this variant is 0.0004222. No homozygotes were found, but eight hemizygotes (male) were observed in 47372 alleles which presumably included both isoforms. There is no reported information from these individuals regarding findings related to ASD when examining clinical information-sharing resources such as Phenome Central, Gene Matcher or ClinVar.</p>
</sec>
<sec id="sec2dot2dot2-ijms-20-03358">
<title>2.2.2. Modeling of Native and R279C Mutant for <italic>SYTL4</italic> Gene</title>
<p>There is limited high-resolution structural information about <italic>SYTL4</italic>. The crystal [<xref ref-type="bibr" rid="B18-ijms-20-03358">18</xref>] and NMR [<xref ref-type="bibr" rid="B19-ijms-20-03358">19</xref>] structure of C2(1) (residues 354-483) and ring domain (residues 43-105) cover only 29% of the protein primary structure. A structural comparison of <italic>SYTL4</italic> and the R279C mutant was carried out using the I-TASSER multiple threading approach [<xref ref-type="bibr" rid="B20-ijms-20-03358">20</xref>]. The protein structure closest to both forms of SYTL4 found in the Protein Data Bank (PDB) [<xref ref-type="bibr" rid="B21-ijms-20-03358">21</xref>] is human synaptotagmin 2 (PDB #4P42) [<xref ref-type="bibr" rid="B22-ijms-20-03358">22</xref>,<xref ref-type="bibr" rid="B23-ijms-20-03358">23</xref>], with TM scores (0.658 and 0.661) and RMSD values (1.15 Å and 0.96 Å), respectively, for the native and R279C form (<xref ref-type="fig" rid="ijms-20-03358-f002">Figure 2</xref>).</p>
</sec>
<sec id="sec2dot2dot3-ijms-20-03358">
<title>2.2.3. Hierarchical Protein Structural Modeling Study of Both Native and R (279) C SYTL4</title>
<p>Both atomic models preserved the canonical C2 structures of synaptotagmins; [<xref ref-type="bibr" rid="B21-ijms-20-03358">21</xref>,<xref ref-type="bibr" rid="B22-ijms-20-03358">22</xref>,<xref ref-type="bibr" rid="B23-ijms-20-03358">23</xref>], however, only the native SYTL4 preserved the extended structure of the ring domain (<xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>) [<xref ref-type="bibr" rid="B18-ijms-20-03358">18</xref>]. An overlay (<xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>C) of two atomic models demonstrated good alignment of the C-terminal C2 domains, whereas the structures of the region comprising both the ring domain and the 279 amino acid change sites for the two SYTL4 forms differed considerably. In the native SYTL4 model, Arg 279 (side chain in red) is part of a large extended loop conformation that appears to be stabilized by an apparent salt bridge formed between it and Asp60 (side chain in Salmon) in the ring domain. The distance (3.116 Å) calculated between the Arginine guanidinium nitrogen and Asp carboxyl oxygen (magnified in <xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>B) is well within the threshold distance observed for salt bridges in a comprehensive survey of crystal structures [<xref ref-type="bibr" rid="B24-ijms-20-03358">24</xref>]. In the R279C model, Cys279 is in a beta sheet, with no apparent hydrogen bonding contacts observed within distance constraints for such interactions [<xref ref-type="bibr" rid="B25-ijms-20-03358">25</xref>] (<xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>A,B). Our modeling suggests a potential structural change induced by the R279C variant, which eliminates the stabilizing Arg279-Asp60 salt bridge and, therefore, leads to significant structural changes in the N-terminal half of the SYTL4.</p>
</sec>
<sec id="sec2dot2dot4-ijms-20-03358">
<title>2.2.4. STRING- Protein–Protein Interaction Network Study Reveals Direct Interaction of <italic>SYTL4</italic> with Other Known Autism Genes</title>
<p>SYTL4 directly interacts with three known <italic>ASD</italic> genes, <italic>STX1A, SNAP25</italic> and <italic>STXBP1</italic> (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). <italic>SYTL4</italic> also interacts with 14 other genes, namely, <italic>FGF4</italic>, <italic>STX1B</italic>, <italic>SNAP29</italic>, <italic>RAB3A</italic>, <italic>SNAP23</italic>, <italic>RAB27B</italic>, <italic>RAB8A</italic>, <italic>SNAP47</italic>, <italic>STX4</italic>, <italic>STX19</italic>, <italic>STX3</italic>, <italic>STX11</italic>, <italic>STX2</italic>, and <italic>RAB27A</italic>, whose transcriptome-wide isoform-level multiple related gene family members are known ASD genes (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). SYTL4 also directly interacts with several members of the RAB-family of genes, such as <italic>RAB27A</italic>, <italic>RAB27B</italic>, <italic>RAB8A</italic>, and <italic>RAB3A</italic> [<xref ref-type="bibr" rid="B26-ijms-20-03358">26</xref>] (<xref ref-type="fig" rid="ijms-20-03358-f004">Figure 4</xref>).</p>
</sec>
<sec id="sec2dot2dot5-ijms-20-03358">
<title>2.2.5. SYTL4- Molecular Pathways and Associated Diseases</title>
<p>The molecular pathways of the <italic>SYTL4</italic> gene includes a synaptic vesicle cycle, insulin secretion, AMPK- signaling, and SNARE interactions in vesicular transport (<xref ref-type="table" rid="ijms-20-03358-t001">Table 1</xref>). Diseases associated with synaptic vesicle cycle defects include early infantile epileptic encephalopathy and defects in insulin secretion including defects in degradation of gangliosides which are abundantly expressed in the nervous system. The deficiency of certain gangliosides will affect the regenerative ability of injured hypoglossal nerves [<xref ref-type="bibr" rid="B27-ijms-20-03358">27</xref>]. Lastly, defective SNARE interactions in vesicular transport have been implicated in CEDNIK-syndrome, which includes cerebral dysgenesis and neuropathy. All the noted pathways and their associated diseases broadly impact nervous system function which are relevant to autism (<xref ref-type="table" rid="ijms-20-03358-t001">Table 1</xref>) [<xref ref-type="bibr" rid="B26-ijms-20-03358">26</xref>].</p>
</sec>
<sec id="sec2dot2dot6-ijms-20-03358">
<title>2.2.6. SYTL4- Networks of Biological Processes</title>
<p>As presented in <xref ref-type="table" rid="ijms-20-03358-t002">Table 2</xref> [<xref ref-type="bibr" rid="B26-ijms-20-03358">26</xref>], extensive biological processes of the <italic>SYTL4</italic> gene pertain to synaptic vesicle functions, including neurotransmitter secretion and regulation of signaling, RAB protein signal transduction, glutamate secretion, neuro-muscular synaptic transmission, and axonogenesis, all of which are relevant for proper neuronal function, and thus important in autism.</p>
</sec>
<sec id="sec2dot2dot7-ijms-20-03358">
<title>2.2.7. SYTL4- Molecular Functions</title>
<p>The molecular function of the <italic>SYTL4</italic> gene includes syntaxin binding, which is essential for neurotransmission (<xref ref-type="table" rid="ijms-20-03358-t003">Table 3</xref>) [<xref ref-type="bibr" rid="B26-ijms-20-03358">26</xref>] and directly interacts with syntaxin-binding protein 1 (STXBP1) (<xref ref-type="fig" rid="ijms-20-03358-f004">Figure 4</xref>). Mutations in STXBP1 are associated with infantile-epileptic encephalopathy-4 [<xref ref-type="bibr" rid="B28-ijms-20-03358">28</xref>]. <italic>SYTL4</italic> molecular gene function also relates to synaptosomal-associated protein receptor (SNAPRe) activity which regulates neurotransmitter release to ensure vesicle-to-target specificity [<xref ref-type="bibr" rid="B29-ijms-20-03358">29</xref>]. In addition, the molecular function of the <italic>SYTL4</italic> gene pertains to trimeric-G-protein (GDP binding protein) which plays a pivotal role in signal transduction pathways for numerous hormones and neurotransmitters [<xref ref-type="bibr" rid="B30-ijms-20-03358">30</xref>].</p>
</sec>
<sec id="sec2dot2dot8-ijms-20-03358">
<title>2.2.8. Missense Mutation Causing R (279) C Amino Acid Change Affects the Structures of Canonical <italic>SYTL4</italic> Gene as Well as Its Shorter Isoform</title>
<p>The amino acid change found in our study, R(arg)279C(cys) in exon 9 (<xref ref-type="fig" rid="ijms-20-03358-f001">Figure 1</xref>), is integral for the full length ‘canonical’ sequence of the SYTL4 protein with 671 amino acids. It is also part of the shorter isoform containing 349 amino acids shown in <xref ref-type="fig" rid="ijms-20-03358-f005">Figure 5</xref>. The R&gt;C amino acid variation at residue 279 has been classified by the Human Genome Variation Society (HGVS) as a missense variant (variation ID # rs141441277) and determined to be least common with a Minor Allele Frequency (MAF) of 0.000529801. It is further predicted as “possible damaging” with a PolyPhen score of 0.79, while SIFT predicts the effect of this amino acid change on protein function as “deleterious” (<uri xlink:href="https://gnomad.broadinstitute.org/variant/X-99944930-G-A">https://gnomad.broadinstitute.org/variant/X-99944930-G-A</uri>; Variant Effect Predictor (VEP) program: <uri xlink:href="https://useast.ensembl.org/info/docs/tools/vep/index.html">https://useast.ensembl.org/info/docs/tools/vep/index.html</uri>.</p>
</sec>
<sec id="sec2dot2dot9-ijms-20-03358">
<title>2.2.9. Autism Predictive Human Serum MicroRNAs with Predicted Interaction with Mouse <italic>Sytl4</italic> Gene</title>
<p>Among the total of 298 mouse Sytl4 associated/predicted miRs, three of the five miRs (60%), namely, miR181b-5p, miR320a, and miR130a-3p- are with good ASD predictive power in serum, as identified in <xref ref-type="table" rid="ijms-20-03358-t004">Table 4</xref>. Apart from the five-serum miRNAs with good ASD predictive power, miR106b-5p and miR328- were up and down regulated (respectively) in the serum ASD study. Both miRs have been reported as showing altered expression among schizophrenics [<xref ref-type="bibr" rid="B31-ijms-20-03358">31</xref>,<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. Interestingly, these two miRs have been predicted to interact with mouse <italic>Sytl4</italic> gene (<xref ref-type="table" rid="ijms-20-03358-t004">Table 4</xref>). In addition, four other miRs (miR98, miR103, miR132, and miR320) have been found to be dysregulated in the superior temporal gyrus of ASD [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>] and predicted to interact with mouse <italic>Sytl4</italic> gene. Furthermore, miR106b, miR181b-5p, miR320, and miR328 are differentially expressed in the ASD cerebellar cortex [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-03358">36</xref>] and predicted to interact with mouse <italic>Sytl4</italic> gene (<xref ref-type="table" rid="ijms-20-03358-t004">Table 4</xref>).</p>
</sec>
</sec>
<sec id="sec2dot3-ijms-20-03358">
<title>2.3. Transmembrane Protein 187 (TEM187) Gene</title>
<sec id="sec2dot3dot1-ijms-20-03358">
<title>2.3.1. Structure of <italic>TMEM187</italic> Gene, Expression and Location of the Novel Variant</title>
<p><italic>TMEM187</italic> gene consists of two exons and encodes a multi-pass membrane protein (<xref ref-type="fig" rid="ijms-20-03358-f006">Figure 6</xref>).</p>
<p>The maternally inherited <italic>TMEM187</italic> missense variant lies beyond the last transmembrane helix region at the near terminal end of the <italic>Pfam</italic> domain 8-245aa represented by multiple sequence alignments and hidden Markov models (<uri xlink:href="https://pfam.xfam.org/family/tmem187">https://pfam.xfam.org/family/tmem187</uri>; TMEM187 (PF15100)). The <italic>TMEM187</italic> gene has three transcripts (splice variants) and 35 orthologs.</p>
</sec>
<sec id="sec2dot3dot2-ijms-20-03358">
<title>2.3.2. Deleterious and Damaging Nature of the Novel <italic>TMEM187</italic> Gene Variant</title>
<p>Unlike the <italic>SYTL4</italic> gene variant, the <italic>TMEM187</italic> missense gene variant (c.708G&gt;T; p. Gln236His) is neither found in the Exome Aggregation Consortium (ExAC) database (which includes the 1000 genome data) or in the <italic>Ensemble.org</italic> data base. The nature of this novel Glutamine(Q)236 to Histidine(H) variation in TMEM187 is considered deleterious as determined by the PROVEAN (Protein Variation Effect Analyzer v1.1) score of = −4.474 with prediction cutoff of −2.5; SIFT score as deleterious (0.05); and PolyPhen-2 score as probably damaging (0.432). (<uri xlink:href="http://gnomad.broadinstitute.org/variant/X-153248221-G-T">http://gnomad.broadinstitute.org/variant/X-153248221-G-T</uri>). PROVEAN prediction generated score of −4.47 is termed as deleterious (scores &lt;−2.5 considered deleterious), while the SIFT score of 0.05 approaches 0.0 which is the most damaging score.</p>
</sec>
<sec id="sec2dot3dot3-ijms-20-03358">
<title>2.3.3. TMEM187 Gene Is Expressed in the Brain</title>
<p>The <italic>TMEM187</italic> gene is ubiquitously expressed in all systems including all parts of the brain (<uri xlink:href="www.uniprot.org/uniprot/Q14656">www.uniprot.org/uniprot/Q14656</uri>; <uri xlink:href="www.genecards.org/">www.genecards.org/</uri>).</p>
</sec>
<sec id="sec2dot3dot4-ijms-20-03358">
<title>2.3.4. Latest STRING- Gene Interaction Network Study Reveals Direct Protein–Protein Interactions of TMEM187 with Several Other Known Autism Genes</title>
<p>Analysis of its STRING- network of interactions (<xref ref-type="fig" rid="ijms-20-03358-f007">Figure 7</xref>) reveals that it directly interacts with four known ASD genes, namely <italic>HCFC1</italic>, <italic>TMLHE</italic>, <italic>MECP2</italic>, and <italic>GPHN</italic> (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). Moreover, three other directly interacting genes, namely <italic>UBL4A, RBM25</italic>, and <italic>AKAP4,</italic> though not known ASD genes, do show other transcriptome-wide isoform-level family member genes known as ASD genes: <italic>UBL7</italic>, <italic>RBM27</italic>, <italic>RBM8A</italic>, <italic>RBMS3</italic>, and <italic>AKAP9</italic> (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
</sec>
</sec>
</sec>
<sec id="sec3-ijms-20-03358" sec-type="discussion">
<title>3. Discussion</title>
<p>Our research findings will be discussed related specifically to both the <italic>SYTL4</italic> and <italic>TMEM187</italic> gene variants seen in our patient and evidence for the two gene variants playing a role in the causation of high-functioning autism spectrum disorder.</p>
<sec id="sec3dot1-ijms-20-03358">
<title>3.1. Synaptotagmin-Like 4 (SYTL4) Gene</title>
<p>As an emerging candidate gene for autism with analyzed protein modeling, protein interactome networks, expression profiling and microRNA interactions will follow.</p>
<sec id="sec3dot1dot1-ijms-20-03358">
<title>3.1.1. Protein Structure Altering Rare Variants Have Been Observed to Be More Frequent in Individuals with Autism</title>
<p>Though common variants are a large driving factors in autism spectrum disorder, the effect size of individual common variants is estimated to be small [<xref ref-type="bibr" rid="B38-ijms-20-03358">38</xref>,<xref ref-type="bibr" rid="B39-ijms-20-03358">39</xref>]. Therefore, the search for rare variants exhibiting a much larger individual effect is ongoing. Protein structure-altering rare variants have been observed more frequently in ASD cases, and ASD risks are increased when two rare variants may deleteriously affect both copies for an autosomal protein, or a single copy of an X-chromosomal protein among ASD males [<xref ref-type="bibr" rid="B40-ijms-20-03358">40</xref>]. Rare hemizygous mutations on the X-chromosome are found to be more enriched in male ASD patients compared to controls. Furthermore, if rare hemizygous mutations on the X-chromosome in males alter gene expression known to be present in the brain, then the overall odds-ratio for ASD will be increased [<xref ref-type="bibr" rid="B41-ijms-20-03358">41</xref>].</p>
</sec>
<sec id="sec3dot1dot2-ijms-20-03358">
<title>3.1.2. Deleterious and Damaging Nature of the <italic>SYTL4</italic> Gene Variant</title>
<p>It is important to note that this particular SYTL4 nucleotide variant CGC⇒TGC resulting in p. Arg279Cys (<xref ref-type="fig" rid="ijms-20-03358-f001">Figure 1</xref>) has been predicted through large-scale genomic sequencing studies, such as the 1000 Genome project, and has been judged to be deleterious (SIFT score 0.01) and possibly damaging (Polyphen score 0.79) with a MAF score of 0.0005/2.</p>
<p>It should also be noted that ExAC database which includes the 1000 genomes data, also calls this SYTL4 variant damaging and deleterious based on Polyphen and SIFT, respectively. Our patient being from Spain, according to ExAC, among the European (Non-Finnish) population, the allele frequency for this variant is 0.0004222 without any homozygotes and with eight hemizygotes (male) for 47,372 alleles, which presumably includes both isoforms. There is no information available as to any of these eight hemizygotes, or any other hemizygote being reported as exhibiting ASD in any of the clinical information-sharing resources such as Phenome Central, Gene Matcher and ClinVar.</p>
</sec>
<sec id="sec3dot1dot3-ijms-20-03358">
<title>3.1.3. Randomness of X Chromosome Inactivation Could Render the Mother Asymptomatic</title>
<p>It is important to note that our male heterozygous carrier of the R (279) C variant is expected to be fully penetrant for the mutant allele. The proband’s mother is a heterozygous carrier of the R (279) C variant and due to randomness of X chromosome inactivation may render her as asymptomatic given that the X-linked <italic>SYTL4</italic> gene is not over expressed among females, indicating that it does not escape inactivation [<xref ref-type="bibr" rid="B42-ijms-20-03358">42</xref>]. The proband’s mother is expected to express equally her normal SYTL4 allele along with the mutant allele.</p>
</sec>
<sec id="sec3dot1dot4-ijms-20-03358">
<title>3.1.4. Our Modeling Results Show Large Conformational Changes Proximal to the R (279) C Amino Acid Variation</title>
<p>It is possible that the structure and function of both the canonical and the truncated isoform of SYTL4 protein will be affected, particularly considering their interactions at membrane surfaces. Our modeling results show large conformational changes proximal to the R (279) C amino acid variation within exon 9. The flanking regions contain two known phosphorylatable serines (YTKS (@274) VIDLR (@279) P EDVVHESGS (@289) L) as shown in <xref ref-type="fig" rid="ijms-20-03358-f005">Figure 5</xref>.</p>
</sec>
<sec id="sec3dot1dot5-ijms-20-03358">
<title>3.1.5. Missense Mutations Change the Size or Properties of Amino Acids Preventing the Function of Proteins</title>
<p>A study (reported by our co-authors: SKR, MGB) in whole exome sequencing in females with autism, a non-synonymous missense mutation (X: 99941091; C&gt;G; p.H448D) of the SYTL4 gene was observed in a female with autism and random X-chromosome inactivation (46–54%). This patient additionally harbored four other autosomal missense gene mutations [<xref ref-type="bibr" rid="B16-ijms-20-03358">16</xref>]. Missense mutations are of importance in understanding the structure or function of a protein since they usually occur in amino acid residues of structural or functional significance by changing the size or properties of the amino acid there by preventing the function of that protein [<xref ref-type="bibr" rid="B43-ijms-20-03358">43</xref>,<xref ref-type="bibr" rid="B44-ijms-20-03358">44</xref>]. The effect of such a mutation is additionally dependent on the sequence and structure context of the alteration [<xref ref-type="bibr" rid="B45-ijms-20-03358">45</xref>]. Proteins fold according to minimum free energy [<xref ref-type="bibr" rid="B46-ijms-20-03358">46</xref>]. Only correctly folded proteins can deliver the functional properties of a protein, and even minor changes in the size or properties of an amino acid side chain can alter or prevent the function of the protein [<xref ref-type="bibr" rid="B47-ijms-20-03358">47</xref>]. On the other hand, even large deletions or insertions may be tolerated in numerous positions within a protein [<xref ref-type="bibr" rid="B48-ijms-20-03358">48</xref>].</p>
<p>Protein function and interactions require both stability and specificity. Since most disease-causing mutations produce structural effects, the importance of a specific gene location and protein production is emphasized [<xref ref-type="bibr" rid="B47-ijms-20-03358">47</xref>]. Structural information is needed to fully understand the effects and consequences of mutations, whether disease-causing or used purposefully to modify the properties of a protein. Three-dimensional structures and computer models have been used to elucidate disease mechanisms from specific amino acid substitutions [<xref ref-type="bibr" rid="B49-ijms-20-03358">49</xref>,<xref ref-type="bibr" rid="B50-ijms-20-03358">50</xref>]. For example, in a study of 4236 mutations from 436 genes, mutations at arginine and glycine residues are collectively responsible for about 30% of genetic diseases [<xref ref-type="bibr" rid="B43-ijms-20-03358">43</xref>].</p>
</sec>
<sec id="sec3dot1dot6-ijms-20-03358">
<title>3.1.6. SYTL4 Amino Acid Change R (279) C in Exon 9: RAB-Binding Domain</title>
<p>The amino acid change in our study patient, <italic>SYTL4</italic> R(279)C in exon 9 (<xref ref-type="fig" rid="ijms-20-03358-f001">Figure 1</xref>, <xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref> and <xref ref-type="fig" rid="ijms-20-03358-f005">Figure 5</xref>), has been determined to severely affect the critical functioning of this gene’s encoded RAB protein binding region at its N-terminal [<xref ref-type="bibr" rid="B51-ijms-20-03358">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>], which is perhaps analogous to the effect of a significant change in Sytl4 gene expression observed among the altered protein networks in the mouse brain proteome in a mouse model of anxiety [<xref ref-type="bibr" rid="B12-ijms-20-03358">12</xref>]. The SYTL4 RAB-Binding Domain within which lies D[Asp], at 60 takes part in the apparent salt bridge formation with R[Arg] at 279 only in the native protein configuration with the presence of mutant C[Cys] at 279 leading to the formation of an extended beta-pleated sheet (see <xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>A,B).</p>
</sec>
<sec id="sec3dot1dot7-ijms-20-03358">
<title>3.1.7. Effect of the R[Arg]⇒C[Cys] Amino Acid Change at 279 on the functionality of the RAB-Binding Domain</title>
<p>Our analysis of the mutant and native SYTL4 protein structure models shows that in the native protein, arginine (R279) forms an apparent salt bridge with aspartic acid (D60) (<xref ref-type="fig" rid="ijms-20-03358-f002">Figure 2</xref> and <xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>A). This arginine is part of a large extended loop conformation that appears to be stabilized by the apparent salt bridge formed between it and Asp60 within the RAB-Binding Domain [aa 4-122] and the Ring Domain [aa 43-105] (<xref ref-type="fig" rid="ijms-20-03358-f002">Figure 2</xref> and <xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>A).</p>
<p>In our R (279) C mutant protein structure model (<xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>B), cysteine (C279) is located amidst a beta sheet with no apparent hydrogen bonding contacts observed within distance constraints for such interactions. Our modeling suggests a potential structural change induced by the R (279) C variation eliminating the stabilizing Arg279-Asp60 salt bridge and leads to significant structural changes in the N-terminal half of SYTL4 (<xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>B,C). This change could very well affect the functionality of the RAB-Binding Domain, not only for the canonical-full-length SYTL4 protein (isoform-1), but also for the truncated SYTL4 protein: isoform-2 (<xref ref-type="fig" rid="ijms-20-03358-f005">Figure 5</xref>).</p>
</sec>
<sec id="sec3dot1dot8-ijms-20-03358">
<title>3.1.8. Potentially Deleterious R (279) C Amino Acid Change “Likely” To Affect Its Neighboring Active Phosphorylation Sites</title>
<p>Given our modeling and profiling results, large conformational changes were seen proximal to the R279C amino acid variation within exon 9. Flanking regions do contain two known phosphorylatable serines (YTKS (@274) VIDLR (@279) P EDVVHESGS (@289) L) (<xref ref-type="fig" rid="ijms-20-03358-f005">Figure 5</xref>). The structure and function of both canonical and truncated isoforms of the SYTL4 protein may be affected, particularly considering their interactions at membrane surfaces.</p>
</sec>
<sec id="sec3dot1dot9-ijms-20-03358">
<title>3.1.9. Role of Arginine (R279) in SYTL4 Protein Structure and Function</title>
<p>The missense mutation identified in our study causes a change in the amino acid at 279 from R [Arginine] to C [Cysteine] (<xref ref-type="fig" rid="ijms-20-03358-f001">Figure 1</xref> and <xref ref-type="fig" rid="ijms-20-03358-f002">Figure 2</xref>B). Arginine is a large polar amino acid with sidechains that prefers to reside in an aqueous environment and is found more commonly on the surface of a protein. SYTL4 is a protein that anchors to the cell membrane and is exposed to both sides of the membrane by aqueous environments of the luminal and cytoplasmic sides. The C2 domain of SYTL4 protein facilitates binding of this protein to cell membranes and is often found in the active centers of proteins that bind phosphorylated substrates [<xref ref-type="bibr" rid="B53-ijms-20-03358">53</xref>,<xref ref-type="bibr" rid="B54-ijms-20-03358">54</xref>].</p>
<p>The arginine (R279) residue is in-fact located in between two Serine(S) residues at 274 and 289- positions (YTKS (@274) VIDLR (@279) PEDVVHESGS (@289) L) (<xref ref-type="fig" rid="ijms-20-03358-f005">Figure 5</xref>) and is shown to undergo post-translational phosphorylation [<xref ref-type="bibr" rid="B55-ijms-20-03358">55</xref>,<xref ref-type="bibr" rid="B56-ijms-20-03358">56</xref>,<xref ref-type="bibr" rid="B57-ijms-20-03358">57</xref>]. Arginine is capable of “salt bridging” by forming non-bonded and hydrogen-bonded paired electrostatic interactions between acidic carboxyl groups and basic amino groups in single or adjacent protein chains [<xref ref-type="bibr" rid="B58-ijms-20-03358">58</xref>]. One important role of “salt bridging” is connecting protein subunits or joining two secondary structures to form quaternary structures where they can connect as many as five secondary structure units [<xref ref-type="bibr" rid="B58-ijms-20-03358">58</xref>].</p>
</sec>
<sec id="sec3dot1dot10-ijms-20-03358">
<title>3.1.10. Arginine Disfavors Cysteine for Substitution</title>
<p>Given the above contrasting basic differences between arginine and cysteine in their properties and their role in protein structure and function, arginine disfavors cysteine for substitution, particularly in extracellular and membrane proteins, such as SYTL4. Since such substitution can be devastating to protein stability and function given the loss of arginine’s ability to create stabilizing hydrogen bonds, the substituted cysteine residue’s ability to alter the native three-dimensional conformation of the protein molecule is important [<xref ref-type="bibr" rid="B44-ijms-20-03358">44</xref>]. Thus, the potential for a structural and functional change induced by the SYTL4 R279C amino acid change is consistent with the noted physiochemical differences between arginine and cysteine [<xref ref-type="bibr" rid="B44-ijms-20-03358">44</xref>].</p>
</sec>
<sec id="sec3dot1dot11-ijms-20-03358">
<title>3.1.11. Dysfunction of Evolutionarily Conserved RAB-Binding GTPases Play a Role in Autism and Neuronal Disorders</title>
<p>Among the transcriptome-wide RAB family of genes, <italic>RAB2A</italic>, <italic>RAB11FIP5</italic>, <italic>RAB19</italic>, <italic>RAB39B</italic>, and <italic>RAB43</italic> are also known ASD genes [<xref ref-type="bibr" rid="B59-ijms-20-03358">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-03358">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03358">61</xref>] (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>) and SYTL4 protein interacts with several other members of the RAB family of proteins including RAB3A, RAB8A, RAB27A, and RAB27B (<xref ref-type="fig" rid="ijms-20-03358-f004">Figure 4</xref>). Therefore, the defect in the RAB protein-binding region in the N-terminal half of the SYTL4 protein is due to the R (279) C amino acid variant and may be a causal factor for the high-functioning autism in our patient.</p>
<p>In addition, the <italic>SYTL4</italic> gene directly interacts with Syntax Binding Protein 1 (STXBP1). Both SYTL4 and STXBP1 are known to interact with RAB3A. STXBP1 interaction with RAB3A promotes RAB3A dissociation from the vesicle membrane (<uri xlink:href="https://www.uniprot.org/uniprot/P61764">https://www.uniprot.org/uniprot/P61764</uri>). SYTL4 protein additionally interacts with several other members of the RAB family of proteins, including RAB3A, RAB8A, RAB27A, and RAB27B. Further, RAB-binding domain of SYTL4 serves as a preferred effector binding site for the GTP-bound form of the RAB27A protein that regulates the exocytosis of secretary granules [<xref ref-type="bibr" rid="B62-ijms-20-03358">62</xref>,<xref ref-type="bibr" rid="B63-ijms-20-03358">63</xref>,<xref ref-type="bibr" rid="B64-ijms-20-03358">64</xref>]. RAB27A binds to the N-terminus SLP homology domains 1 and 2 of SYTL4 protein and the C-terminal domain (<xref ref-type="fig" rid="ijms-20-03358-f001">Figure 1</xref> and <xref ref-type="fig" rid="ijms-20-03358-f002">Figure 2</xref>A). It appears to play a role in the localization of RAB27A to specific sites in a cell [<xref ref-type="bibr" rid="B51-ijms-20-03358">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>,<xref ref-type="bibr" rid="B65-ijms-20-03358">65</xref>]. Upregulation of RAB27A protein in basal forebrain neurons has been associated with mild cognitive impairment and Alzheimer’s disease [<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>].</p>
<p>Further, specific evolutionarily conserved RAB-binding GTPases function as regulators of membrane trafficking and binding and act as binary molecular switches turned on by binding GTP and off by hydrolyzing GTP to GDP [<xref ref-type="bibr" rid="B66-ijms-20-03358">66</xref>]. Their dysfunction through mutations has also been shown to play a crucial role in causing diverse patho-physiologies including X-linked mental retardation associated with autism, epilepsy and macrocephaly. This suggests a major role for specific RAB- binding effector proteins, such as SYTL4 and interacting RAB-activating GTPases (RAB GTPases) in the maintenance of normal neuronal function [<xref ref-type="bibr" rid="B51-ijms-20-03358">51</xref>,<xref ref-type="bibr" rid="B59-ijms-20-03358">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-03358">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03358">61</xref>,<xref ref-type="bibr" rid="B64-ijms-20-03358">64</xref>,<xref ref-type="bibr" rid="B65-ijms-20-03358">65</xref>,<xref ref-type="bibr" rid="B66-ijms-20-03358">66</xref>].</p>
</sec>
<sec id="sec3dot1dot12-ijms-20-03358">
<title>3.1.12. Significance of Defect in RAB- Protein Binding Region of N-Terminal Half of SYTL4 Protein due to R (279) C Amino Acid Variant</title>
<p>The potentially deleterious R (279) C amino acid change could critically affect the RAB-binding domain of SYTL4 proteins. Our analysis of the mutant and native SYTL4 protein structure models shows that in the native protein, arginine (R279) forms an apparent salt bridge with aspartic acid (D60). This arginine is part of a large extended loop conformation that appears to be stabilized by the apparent salt bridge formed between it and Asp60 within the RAB-Binding Domain [aa 4-122] and the Ring Domain [aa 43-105].</p>
<p>In our R279C mutant model, cysteine (C279) is located amidst a beta sheet with no apparent hydrogen bonding contacts observed within distance constraints for such interactions. Our modeling thus suggests a potential structural change induced by the R279C variation which eliminates the stabilizing Arg279-Asp60 salt bridge and leads to significant structural changes in the N-terminal half of SYTL4 (<xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>B). This could very well affect the functionality of the RAB-Binding Domain, not only for the canonical-full-length SYTL4 protein (isoform-1), but also for the truncated SYTL4 protein: isoform-2.</p>
</sec>
<sec id="sec3dot1dot13-ijms-20-03358">
<title>3.1.13. SYTL4-Protein-Protein Interactions with RAB27A and with Other RAB-Family of Genes</title>
<p>As seen in <xref ref-type="fig" rid="ijms-20-03358-f004">Figure 4</xref>, the SYTL4 protein directly interacts with several members of the RAB (Ras-Associated proteins in Brain) family of proteins, RAB3A, RAB8A, RAB27A, and RAB27B. Further, RAB- binding domain of the SYTL4 protein serves as a preferred effector binding site for the GTP-bound form of RAB27A protein that regulates the exocytosis of secretary granules [<xref ref-type="bibr" rid="B62-ijms-20-03358">62</xref>,<xref ref-type="bibr" rid="B63-ijms-20-03358">63</xref>,<xref ref-type="bibr" rid="B64-ijms-20-03358">64</xref>]. Among the RAB- family of genes, <italic>RAB2A</italic>, <italic>RAB11FIP5</italic>, <italic>RAB19</italic>, <italic>RAB39B</italic>, and <italic>RAB43</italic> are known ASD genes [<xref ref-type="bibr" rid="B59-ijms-20-03358">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-03358">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03358">61</xref>] (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
</sec>
<sec id="sec3dot1dot14-ijms-20-03358">
<title>3.1.14. Upregulation of RAB27A Protein Associated with Mild Cognitive Impairment and Alzheimer Disease</title>
<p>RAB27A binds to the N-terminus SLP homology domains 1 and 2 of the SYTL4 protein, and the C-terminal domain seems to play a role in the localization of RAB27A to specific sites in a cell [<xref ref-type="bibr" rid="B51-ijms-20-03358">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>,<xref ref-type="bibr" rid="B65-ijms-20-03358">65</xref>]. It important to note that upregulation of the RAB27A protein in basal forebrain neurons has been associated with mild cognitive impairment and Alzheimer disease [<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>].</p>
</sec>
<sec id="sec3dot1dot15-ijms-20-03358">
<title>3.1.15. Dysfunction of Conserved RAB-Binding GTPases Play a Role in X-Linked Mental Retardation with Autism</title>
<p>As indicated earlier, specific evolutionarily conserved RAB-binding GTPases do function as regulators of membrane trafficking and binding by acting as binary molecular switches that are turned on by binding GTP and off by hydrolyzing GTP to GDP. Their dysfunction through mutations has been shown to play a crucial role in causing diverse patho-physiologies including X-linked mental retardation associated with autism, epilepsy, and macrocephaly, suggesting a major role for specific RAB-binding effector proteins, such as the SYTL4, and interacting RAB-activating GTPases (RAB- GTPases) in the maintenance of normal neuronal function [<xref ref-type="bibr" rid="B51-ijms-20-03358">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>,<xref ref-type="bibr" rid="B59-ijms-20-03358">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-03358">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03358">61</xref>,<xref ref-type="bibr" rid="B66-ijms-20-03358">66</xref>,<xref ref-type="bibr" rid="B67-ijms-20-03358">67</xref>].</p>
</sec>
<sec id="sec3dot1dot16-ijms-20-03358">
<title>3.1.16. <italic>SYTL4</italic> Gene Is Relevant to Neuronal System Function and Disorders</title>
<p>The <italic>SYTL4</italic> gene is relevant for neuronal system development, function and behavior, and is implicated in neurological and psychological diseases (Entrez Gene ID # 94121 (Human); ID # 27359 (Mouse). The <italic>SYTL4</italic> gene expression is down regulated in the dorsal raphe nucleus of patients with major depressive disorders [<xref ref-type="bibr" rid="B11-ijms-20-03358">11</xref>]. In addition, in a mouse model of anxiety, significant changes in <italic>Sytl4</italic> were observed among the altered protein networks in the brain proteome [<xref ref-type="bibr" rid="B12-ijms-20-03358">12</xref>].</p>
</sec>
<sec id="sec3dot1dot17-ijms-20-03358">
<title>3.1.17. SYTL4 Protein Is Abundantly Expressed in the Bed Nucleus of Stria Terminalis and Is Upregulated in Male Brain</title>
<p>The bed nucleus of stria terminalis (BNST) is a heterogeneous complex limbic forebrain structure, which plays an important role in controlling autonomic, neuroendocrine, and behavioral responses, and is thought to serve as a key relay connecting limbic forebrain structures to hypothalamic and brainstem regions associated with autonomic and neuroendocrine functions [<xref ref-type="bibr" rid="B10-ijms-20-03358">10</xref>,<xref ref-type="bibr" rid="B14-ijms-20-03358">14</xref>]. Its control of physiological and behavioral activity is mediated by local action of numerous neurotransmitters [<xref ref-type="bibr" rid="B68-ijms-20-03358">68</xref>]. Therefore, one could argue that the abundantly-expressed SYTL4 mutant protein in the bed nucleus of stria terminalis could potentially affect normal behavioral responses resulting in an autistic phenotype, given that <italic>Sytl4</italic> is upregulated in the brain of male mice, specifically in the posteromedial area of the medial BNST [<xref ref-type="bibr" rid="B9-ijms-20-03358">9</xref>].</p>
<p>Furthermore, in mouse brain, the expression of Sytl4 protein is sexually dimorphic due to the sex hormone (estrogen and testosterone)-specific control of this gene and the developmental influence of sex hormone can lead to enduring effects on brain and behavior [<xref ref-type="bibr" rid="B9-ijms-20-03358">9</xref>,<xref ref-type="bibr" rid="B69-ijms-20-03358">69</xref>]. Mice with targeted disruptions of the <italic>Sytl4</italic> gene exhibit specific deficits in sex-specific behavior and deficits. <italic>Sytl4</italic> is required for patterning male sexual behavior [<xref ref-type="bibr" rid="B9-ijms-20-03358">9</xref>]. Given the increased risk estimates of ASD among males [<xref ref-type="bibr" rid="B70-ijms-20-03358">70</xref>,<xref ref-type="bibr" rid="B71-ijms-20-03358">71</xref>], the overall odds-ratio for ASD increases if the rare hemizygous mutation on the X-chromosome pertains to gene expression that is known to express in the brain [<xref ref-type="bibr" rid="B41-ijms-20-03358">41</xref>].</p>
</sec>
<sec id="sec3dot1dot18-ijms-20-03358">
<title>3.1.18. Targeted Knockout Mutant Mammalian Phenotypes for <italic>Sytl4</italic> Includes Abnormal Behavior and Abnormal Neurological Phenotype</title>
<p>The amino acid changes of SYTL4 R279C in exon 9 in our patient have been determined to severely affect the RAB protein-binding region at its N-terminal [<xref ref-type="bibr" rid="B51-ijms-20-03358">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>], which may be analogous to the partial or full effect of targeted Null/Knockout mutant <italic>Sytl4</italic> mammalian phenotypes. Gomi et al. [<xref ref-type="bibr" rid="B16-ijms-20-03358">16</xref>] found that a targeted (Null/Knockout) mutation for Granuphilin (<italic>Sytl4</italic>) in XY-male mouse with 129P2/OlaHsd- genetic background replaced exons 3–5: targeted mutation 1, Tetsuro Izumi (tm1Tiz): Grn−/Y (<italic>Sytl4</italic> tm1Tiz/Y) particularly affected its endocrine and nervous systems with abnormal corticotroph morphology and hypersecretion of adrenocorticotropin [<xref ref-type="bibr" rid="B16-ijms-20-03358">16</xref>,<xref ref-type="bibr" rid="B72-ijms-20-03358">72</xref>]. Importantly, the same mammalian-targeted <italic>Sytl4</italic> knock-outs in 129P2/OlaHsd*C3H/He (<italic>Sytl4</italic>tm1Tiz/Sytl4tm1Tiz) and in 129P2/OlaHsd (<italic>Sytl4</italic>tm1Tiz/Y) have been associated with abnormal behavior and neurological phenotypes encompassing alertness, behavioral response to light, circadian rhythm, cognition, consumption behavior, emotion/affect behavior, grooming behavior, impulsive behavior, motor capabilities/coordination/movement, sensory capabilities/reflexes/nociception, sheltering behavior, sleep behavior, vocalization, and social interaction [<xref ref-type="bibr" rid="B13-ijms-20-03358">13</xref>,<xref ref-type="bibr" rid="B14-ijms-20-03358">14</xref>].</p>
</sec>
<sec id="sec3dot1dot19-ijms-20-03358">
<title>3.1.19. Targeted <italic>Sytl4</italic> Knock Out Mouse Model Studies Affirm That Defective SYTL4 Protein Function is Likely to Effectuate Neurological and Phenotypic Defects</title>
<p>A wide range of functions of the SYTL4 protein is noted for various cellular components, such as intracellular protein transport and positive regulation of protein secretion involving nucleoplasm, cytoplasm, endosome, centrosome, and plasma membrane which govern diverse molecular functions. These include protein and phospholipid binding, zinc and metal ion binding, clathrin binding, and neurexin protein binding. One could postulate that the observed low birth weight and height, as well as the down-slanting palpebral fissures, mild hypertelorism, thin upper lip, and pointed chin seen in our patient could relate to the abnormal SYTL4 protein. These phenotypic abnormalities are perhaps not observable in the Tetsuro Izumi (tm1Tiz) and Grn−/Y (<italic>Sytl4</italic> tm1Tiz/Y) mice models [<xref ref-type="bibr" rid="B16-ijms-20-03358">16</xref>,<xref ref-type="bibr" rid="B72-ijms-20-03358">72</xref>], however, decreased body weight has been reported in targeted <italic>Sytl4</italic> knock-out (Sytl4tm1Tiz/Sytl4tm1Tiz) mice with 129P2/OlaHsd*C3H/He genetic background. Thus, targeted <italic>Sytl4</italic> knock out mouse model studies affirm that defective SYTL4 protein function may effectuate neurological and phenotypic defects.</p>
</sec>
<sec id="sec3dot1dot20-ijms-20-03358">
<title>3.1.20. SYTL4 Protein Directly Interacts with Proteins Known to Cause Autism</title>
<p>Our protein–protein interactions study of the <italic>SYTL4</italic> gene shows that the SYTL4 protein directly interacts with three other proteins which are known to cause autism, namely, STX1A, SNAP25 and STXBP1 (<xref ref-type="fig" rid="ijms-20-03358-f004">Figure 4</xref>; <uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). In addition, the SYTL4 protein directly interacts with FGF4, STX1B, SNAP29, SNAP23, SNAP47, RAB3A, RAB27A, RAB27B, RAB8A, STX4, STX19, STX3, STX11, and STX2 whose numerous transcriptome-wide isoforms are known as autism genes (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
</sec>
<sec id="sec3dot1dot21-ijms-20-03358">
<title>3.1.21. <italic>SYTL4</italic> Gene Sequence Shows Similarity to a Known Autism Gene: <italic>SYT1</italic></title>
<p>Moreover, the <italic>SYTL4</italic> gene sequence alignment shows similarity to the <italic>SYT1</italic> gene which is a known autism gene (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). Yet another larger Synaptotagmin gene family member, <italic>SYT17</italic>, is also a known ASD gene (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
</sec>
<sec id="sec3dot1dot22-ijms-20-03358">
<title>3.1.22. <italic>SYTL4</italic> Gene Sequence Alignment Shows Similarity to <italic>SYT1</italic>(Synaptotagmin 1) Gene Which is a Known ASD Gene</title>
<p>Although the <italic>SYTL4</italic> gene is presented here as a candidate gene, its transcriptome-wide isoform-level related gene family members, such as <italic>SYT1</italic>, <italic>SYT17,</italic> and <italic>SYT3</italic> are known ASD genes (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). Moreover, the <italic>SYTL4</italic> gene sequence alignment shows similarity to the <italic>SYT1</italic> gene [<xref ref-type="bibr" rid="B70-ijms-20-03358">70</xref>]. Synaptotagmins are integral membrane proteins of synaptic vesicles thought to serve as Ca (2+) sensors in the process of vesicular trafficking and exocytosis. Calcium binding to synaptotagmin-1 participates in triggering neurotransmitter release at the synapse [<xref ref-type="bibr" rid="B70-ijms-20-03358">70</xref>].</p>
</sec>
<sec id="sec3dot1dot23-ijms-20-03358">
<title>3.1.23. Direct Protein-Protein STRING Interactions of the <italic>SYTL4</italic> Gene with Other ASD Genes</title>
<p>More significantly, the SYTL4 protein directly interacts with three known ASD proteins, STX1A, STXBP1 and SNAP25 (<xref ref-type="fig" rid="ijms-20-03358-f004">Figure 4</xref>) (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). STX1A (Syntaxin 1A (brain)) encodes a protein involved in the regulation of serotonergic and GABAergic systems and its expression is altered in autism [<xref ref-type="bibr" rid="B70-ijms-20-03358">70</xref>]. Rare single gene mutations in <italic>STX1A</italic> have been implicated in ASD. This gene is located at 7q11.23. Common <italic>STX1A</italic> variants are nominally associated with high-functioning autism and Asperger syndrome (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). This protein governs the release and uptake of extracellular vesicles in the nervous system and glial cells facilitating transcellular communication [<xref ref-type="bibr" rid="B73-ijms-20-03358">73</xref>] and serves as a key molecule in ion channel regulation and synaptic exocytosis (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
<p>The <italic>SYTL4</italic> gene also directly interacts with Syntax binding protein 1 (STXBP1). A frameshift mutation in the <italic>STXBP1</italic> gene has been implicated in a study of quartet families with autism spectrum disorder [<xref ref-type="bibr" rid="B74-ijms-20-03358">74</xref>,<xref ref-type="bibr" rid="B75-ijms-20-03358">75</xref>,<xref ref-type="bibr" rid="B76-ijms-20-03358">76</xref>] and is a known autism gene (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). <italic>SYTL4</italic> recruits and binds <italic>STXBP1</italic> to promote exocytosis [<xref ref-type="bibr" rid="B26-ijms-20-03358">26</xref>] (<uri xlink:href="http://www.genecards.org/cgi-bin/carddisp.pl?gene=STXBP1&amp;keywords=STXBP">http://www.genecards.org/cgi-bin/carddisp.pl?gene=STXBP1&amp;keywords=STXBP</uri>]. It is important to note that like <italic>STXBP1</italic>, <italic>SYTL4</italic> is also associated with early onset epileptic encephalopathy and both these genes are expressed in every part of the brain [<uri xlink:href="http://www.genecards.org/">http://www.genecards.org/</uri>). <italic>SYTL4</italic> as well as <italic>STXBP1</italic> are known to be expressed in the frontal cortex and brain and are essential for protein–protein interactions at synapses and the neurotransmitter release cycle in human neurons (<uri xlink:href="http://www.genecards.org/">http://www.genecards.org/</uri>). <italic>STXBP1</italic> is overexpressed in the frontal cortex and even heterozygous mutations cause early onset epileptic encephalopathy, specifically through presynaptic impairment and autism [<xref ref-type="bibr" rid="B74-ijms-20-03358">74</xref>,<xref ref-type="bibr" rid="B75-ijms-20-03358">75</xref>,<xref ref-type="bibr" rid="B76-ijms-20-03358">76</xref>]. Like <italic>STXBP1</italic>, <italic>SYTL4</italic> is also associated with early onset epileptic encephalopathy and is expressed in brain regions (<uri xlink:href="http://www.genecards.org/">http://www.genecards.org/</uri>). Polymorphisms in the <italic>SNAP25</italic> (Synaptosomal-associated protein, 25 kDa) gene are associated with ADHD. <italic>SNAP25</italic>+/− mice also exhibit hyperactivity and cognitive and social impairment [<xref ref-type="bibr" rid="B77-ijms-20-03358">77</xref>]. In addition to the SYTL4 protein’s direct interactions with three known ASD proteins, STX1A, STXBP1 and SNAP25, it interacts with 14 other genes, namely, <italic>FGF4, STX1B, SNAP29</italic>, <italic>RAB3A</italic>, <italic>SNAP23</italic>, <italic>RAB27B</italic>, <italic>RAB8A</italic>, <italic>SNAP47</italic>, <italic>STX4</italic>, <italic>STX19</italic>, <italic>STX3</italic>, <italic>STX11</italic>, <italic>STX2</italic>, and <italic>RAB27A</italic>, whose numerous transcriptome-wide isoform-level multiple gene family members are known ASD genes (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
</sec>
<sec id="sec3dot1dot24-ijms-20-03358">
<title>3.1.24. <italic>SYTL4</italic>- Molecular Pathways, Biological Processes and Molecular Functions</title>
<p>Significant <italic>SYTL4</italic> gene-involved molecular pathways are the synaptic vesicle cycle, insulin secretion, AMPK-signaling pathway, and SNARE interactions (<xref ref-type="table" rid="ijms-20-03358-t001">Table 1</xref>). The synaptic vesicle cycle pertains to synaptic vesicles that are filled with neurotransmitters by active transport, and the diseases that are associated with defects in this cycle are early infantile epileptic encephalopathy; centronuclear myopathy; episodic ataxias; and familial or sporadic hemiplegic migraine. Insulin secretion is regulated by several hormones and neurotransmitters, and the diseases associated with this pathway are defects in the degradation of ganglioside and type II diabetes mellitus. AMPK signaling acts as a sensor of cellular energy status while SNARE interactions mediate the docking of synaptic vesicles with the presynaptic membrane in neurons. Diseases associated with defective SNARE interactions are pseudohypoparathyroidism and cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma or CEDNIK syndrome (<xref ref-type="table" rid="ijms-20-03358-t001">Table 1</xref>).</p>
<p>The <italic>SYTL4</italic> gene’s extensive biological processes (<xref ref-type="table" rid="ijms-20-03358-t002">Table 2</xref>) pertain to RAB-protein signal transduction along with synaptic vesicle functions, neurotransmitter secretion, regulation of signaling, glutamate secretion, neuro-muscular synaptic transmission, and axonogenesis, which are all relevant for proper neuronal function, and thus also relevant to autism. The <italic>SYTL4</italic> gene’s molecular functions (<xref ref-type="table" rid="ijms-20-03358-t003">Table 3</xref>), biological processes (<xref ref-type="table" rid="ijms-20-03358-t002">Table 2</xref>) and molecular pathways (<xref ref-type="table" rid="ijms-20-03358-t001">Table 1</xref>) are indicative of its significant role in neuronal function that is meaningful in the causation of high-functioning autism in our proband. Moreover, in recent studies, disturbed <italic>SYTL4</italic> gene function has been associated with neuropsychiatric disorders, such as autism, schizophrenia and depression as well as the immune system. It is also considered a major modulator of central nervous system function [<xref ref-type="bibr" rid="B11-ijms-20-03358">11</xref>,<xref ref-type="bibr" rid="B12-ijms-20-03358">12</xref>].</p>
</sec>
<sec id="sec3dot1dot25-ijms-20-03358">
<title>3.1.25. Synaptic Dysfunction in Neurodevelopmental Disorders Is Associated with Autism and Intellectual Disabilities</title>
<p>The SYTL4 modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. It interacts with vesicles containing negatively charged phospholipids in a Ca (2+)-independent manner (<uri xlink:href="http://www.genecards.org/">http://www.genecards.org/</uri>). The significant SYTL4 molecular pathways are the synaptic vesicle cycle, insulin secretion, AMPK-signaling pathway, and SNARE interactions (<xref ref-type="table" rid="ijms-20-03358-t001">Table 1</xref>). Like <italic>SYTL4</italic>, <italic>SYT1</italic>, <italic>STX1A</italic>, <italic>STXBP1</italic> and <italic>SNAP25</italic> genes play an important role in the extravesicular synaptic function of neuronal systems and neurotransmission (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>; <uri xlink:href="www.genecards.org/">www.genecards.org/</uri>). Thus, these proteins are generally involved in the functioning of the synaptic vesicles’ (or neurotransmitter vesicles) cycle to facilitate synaptic vesicle exocytosis by which a synaptic vesicle fuses with the plasma membrane of the pre-synaptic axon terminal and releases its contents in the synaptic cleft, which is essential for propagating nerve impulses between neurons and are constantly created by the cells to facilitate transcellular communication [<xref ref-type="bibr" rid="B73-ijms-20-03358">73</xref>].</p>
<p>It should be noted that the <italic>SYTL4</italic> mRNAs are found in extracellular vesicles and stimulate target cells to translate into active protein [<xref ref-type="bibr" rid="B78-ijms-20-03358">78</xref>]. The <italic>SNAP25</italic> gene encodes t-SNARE which is involved in the molecular regulation of neurotransmitter release that associates with proteins in vesicle docking and membrane fusion. It may play an important role in the synaptic function of specific neuronal systems [<xref ref-type="bibr" rid="B77-ijms-20-03358">77</xref>] (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). Similarly, STXBP1 protein is essential for neurotransmission and binds to syntaxin, a component of the synaptic vesicle fusion machinery (<uri xlink:href="https://www.uniprot.org/uniprot/P61764">https://www.uniprot.org/uniprot/P61764</uri>).</p>
<p>Genes that regulate presynaptic processes ultimately affect neurotransmitter release when disturbed [<xref ref-type="bibr" rid="B79-ijms-20-03358">79</xref>,<xref ref-type="bibr" rid="B80-ijms-20-03358">80</xref>]. Synaptic dysfunction in neurodevelopmental disorders is associated with autism and intellectual disabilities [<xref ref-type="bibr" rid="B81-ijms-20-03358">81</xref>,<xref ref-type="bibr" rid="B82-ijms-20-03358">82</xref>,<xref ref-type="bibr" rid="B83-ijms-20-03358">83</xref>,<xref ref-type="bibr" rid="B84-ijms-20-03358">84</xref>] as noted by Baker et al. [<xref ref-type="bibr" rid="B80-ijms-20-03358">80</xref>] who reported the first case of a rare missense variant (<italic>I368T</italic>) in the Synaptotagmin1 (<italic>SYT1</italic>) gene causing a human neurodevelopmental disorder. It has a dominant negative effect involving both synaptic vesicle exocytosis and endocytosis [<xref ref-type="bibr" rid="B80-ijms-20-03358">80</xref>].</p>
<p>Significant molecular pathways, functions and biological processes (<xref ref-type="table" rid="ijms-20-03358-t001">Table 1</xref>, <xref ref-type="table" rid="ijms-20-03358-t002">Table 2</xref> and <xref ref-type="table" rid="ijms-20-03358-t003">Table 3</xref>) of the <italic>SYTL4</italic> gene include synaptic vesicle cycle and fusion, exocytosis and neurotransmitter secretion, akin to the molecular functions of its directly interacting known ASD genes: <italic>STXBP1</italic> and <italic>SNAP25</italic>. Therefore, deficiency in the functioning of the SYTL4 protein due to the R (279) C amino acid change affects the canonical structures of the <italic>SYTL4</italic> gene as well as its shorter isoform affecting synaptic vesicle cycle and fusion, exocytosis, and neurotransmitter secretion likely to cause autism and intellectual disabilities.</p>
</sec>
<sec id="sec3dot1dot26-ijms-20-03358">
<title>3.1.26. ASD-Predictive MicroRNAs among Mouse <italic>Sytl4</italic>- Interacting MicroRNAs</title>
<p>Our analysis of 298 validated/predicted microRNA interactions with mouse <italic>Sytl4</italic> gene [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>,<xref ref-type="bibr" rid="B85-ijms-20-03358">85</xref>,<xref ref-type="bibr" rid="B86-ijms-20-03358">86</xref>,<xref ref-type="bibr" rid="B87-ijms-20-03358">87</xref>,<xref ref-type="bibr" rid="B88-ijms-20-03358">88</xref>] has identified three of five autism-associated serum miRs (60%), namely, miR181b-5p, miR320a, and miR130a-3p, which have good predictive power in serum [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. Among these three miRs, miR320 has the greatest ASD predictive power reported in serum as well as in the superior temporal gyrus and cerebellar cortex of ASD individuals [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>,<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]. In addition, 5 of 13 (38%) miRs that were differentially expressed in ASD serum samples were predicted to be interacting with mouse <italic>Sytl4</italic> gene [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. Three of these five miRs, namely, miR130a-3p, miR181b-5p, and miR328 are predicted to be associated with the mouse <italic>Sytl4</italic> gene. They have been shown to be differentially expressed in schizophrenics [<xref ref-type="bibr" rid="B31-ijms-20-03358">31</xref>,<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>].</p>
</sec>
<sec id="sec3dot1dot27-ijms-20-03358">
<title>3.1.27. Dysregulation of miR-320—Most Predictive for ASD in Serum and Brain Tissues</title>
<p>Recently, miR-320, along with miR-197 in human follicular fluid were found to be associated with embryonic development potential [<xref ref-type="bibr" rid="B89-ijms-20-03358">89</xref>]. Knocking down miR-320 in mouse oocytes negatively affects embryonic developmental potentially by inhibiting the expression of the Wnt-signaling pathway and therefore miRNAs in human follicular fluid might reflect an effect on embryo quality [<xref ref-type="bibr" rid="B89-ijms-20-03358">89</xref>]. Furthermore, autopsy tissue sections showed concordantly dysregulated miR-320a and voltage-dependent anion channel 1 levels in HIV-1 patients suffering from mild cognitive impairment [<xref ref-type="bibr" rid="B90-ijms-20-03358">90</xref>]. One could consider dysregulation of miR-320 as the most predictive for ASD in serum and brain tissues, since it was also found to be dysregulated in the superior temporal gyrus of ASD specimens [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]. Additionally, miR-320 and miR-197 are differentially expressed in the ASD cerebellar cortex [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-03358">36</xref>]. Given the fact that miR-320 has been predicted to interact with mouse <italic>Sytl4</italic> gene, it gives credence to the <italic>SYTL4</italic> gene as a plausible new gene ASD.</p>
</sec>
<sec id="sec3dot1dot28-ijms-20-03358">
<title>3.1.28. <italic>SYTL4</italic> Interacting miR181b-1- Being Predictive of ASD</title>
<p>The micro RNA second in line to miR320 is miR181b-1 as the most predictive for ASD. It not only showed good predictive power for ASD in serum [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] but is also differentially expressed in the ASD cerebellar cortex [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-03358">36</xref>]. Unlike miR-320, miR181b-1 has additionally been found to show altered expression in the cortical regions in schizophrenia [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>], supporting the contention that ASD and schizophrenia share common neurobiological features [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. In a recent study, significant down-regulation of miRNA-181b expression in schizophrenics predicted improvement of negative symptoms to treatment, and thus miRNA-181b is predicted to serve as a potential plasma-molecular marker for antipsychotic responses [<xref ref-type="bibr" rid="B91-ijms-20-03358">91</xref>].</p>
</sec>
<sec id="sec3dot1dot29-ijms-20-03358">
<title>3.1.29. SYTL4 Interacting miR130a-Being Predictive of ASD</title>
<p>Another potentially important micro RNA is miR130a (miR130a-3p) for prediction of ASD but is lacking corroboration from any ASD brain tissue studies (unlike miR320 and miR181b-1, above). However, like miRNA-181b, miR130a also showed altered expression (serum/cortical) in schizophrenia, again supporting the contention that ASD and schizophrenia share common neurobiological features [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>].</p>
</sec>
<sec id="sec3dot1dot30-ijms-20-03358">
<title>3.1.30. <italic>SYTL4</italic>-Interacting miR106b and miR328 Dysregulated in ASD Cerebellar Cortex and Altered among Schizophrenics</title>
<p>Other SYTL4-associated miRs, miR106b (106b-3p) and miR328, have shown up and down regulation, respectively, in ASD serum and are differentially expressed in the ASD cerebellar cortex [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>]. In addition, both miRs have also been shown to be altered among schizophrenics [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>].</p>
</sec>
<sec id="sec3dot1dot31-ijms-20-03358">
<title>3.1.31. <italic>SYTL</italic> Interacting miR63, miR103, 5nd miR132 Are Dysregulated in Superior Temporal Gyrus of ASD</title>
<p>Other predicted <italic>SYTL4</italic>-interacting miRs, such as, miR93, miR103 (miR103-1 and miR103-2), and miR132, have been found to be dysregulated in superior temporal gyrus of ASD [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]. Thus, a total of eight microRNAs which are predicted to be associated with mouse <italic>Sytl4</italic> are found to be altered in ASD serum and/or brain, thereby, augmenting our contention that the <italic>SYTL4</italic> gene is a plausible new ASD candidate gene. Fifty percent (4/8) of the ASD-associated miRs (miRs106, miRs130a, miRs181b, and miRs328) that are predicated to interact with the mouse <italic>Sytl4</italic> gene are also known to be associated with schizophrenia, supporting the contention that ASD and schizophrenia share common neurobiological features [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>,<xref ref-type="bibr" rid="B92-ijms-20-03358">92</xref>,<xref ref-type="bibr" rid="B93-ijms-20-03358">93</xref>] (<xref ref-type="table" rid="ijms-20-03358-t004">Table 4</xref>).</p>
<p>Fifty percent (4/8) of the ASD-associated mirRs (mirRs93, mirRs103, mirRs132, mirRs320) that are predicted to interact with mouse Sytl4 have also been determined to be dysregulated in superior temporal gyrus of ASD [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]. Yet again, 50% (4/8) of the ASD-associated mirRs (mirRs106b, mirRs181b-5p, mirRs320, mirRs328) predicted to interact with the mouse <italic>Sytl4</italic> have also been determined to be differentially expressed in the ASD cerebellar cortex [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>]. Over expression of miR142-5p, miR142-3p, miR451a, miR144-3p, and miR21-5p has been reported in ASD brain tissue along with hypomethylation of the promoter region of the miR142 gene in the same samples, suggesting dysregulation of these microRNAs [<xref ref-type="bibr" rid="B94-ijms-20-03358">94</xref>]. However, the mouse <italic>Sytl4</italic> gene has not been predicted to interact with any of the miRs that were found to be over expressed by Mor et al. [<xref ref-type="bibr" rid="B94-ijms-20-03358">94</xref>]. Furthermore, these five miRs are not represented among the 13 differentially expressed miRs in ASD serum [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] (<xref ref-type="table" rid="ijms-20-03358-t004">Table 4</xref>). Other studies have also not reported any of the five miRs to be over expressed by Mor et al., [<xref ref-type="bibr" rid="B94-ijms-20-03358">94</xref>] based on specific regions of ASD brains, such as the superior temporal gyrus [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>] and cerebellar cortex [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>].</p>
</sec>
</sec>
<sec id="sec3dot2-ijms-20-03358">
<title>3.2. Transmembrane Protein 187 (TMEM187) Gene</title>
<p><italic>TMEM187</italic> is an emerging candidate gene for autism with a discussion undertaken on protein interactome networks, expression profiling and microRNA interaction studies.</p>
<sec id="sec3dot2dot1-ijms-20-03358">
<title>3.2.1. <italic>TMEM187</italic> Gene Belongs to a Group of Genes Which Host MicroRNA Genes in Their Introns or Exons</title>
<p>At the outset, it should be noted that unlike the <italic>SYTL4</italic> gene, not much is known about the <italic>TMEM187</italic> gene, and there is limited information available regarding its biological processes, molecular pathways and functions or microRNA interactions. The <italic>TMEM187</italic> gene, like <italic>SYTL4</italic>, is a protein-coding gene, but belongs to a group of genes which host microRNA genes in their introns or exons [<xref ref-type="bibr" rid="B17-ijms-20-03358">17</xref>]. However, we introduce the <italic>TMEM187</italic> gene as an emerging candidate gene for autism with our mutation analysis of its novel missense variant c.708G&gt;T; p. Gln236His, its STRING-protein interactome network and its expression profiling.</p>
</sec>
<sec id="sec3dot2dot2-ijms-20-03358">
<title>3.2.2. Novel <italic>TMEM187</italic> Missense Variant c.708G&gt;T: Glutamine(Q)236 Histidine(H)</title>
<p>Unlike the <italic>SYTL4</italic> gene variant, <italic>TMEM187</italic> Glutamine(Q)236 Histidine(H) variant in our patient is not found in the Exome Aggregation Consortium (ExAC) database. It is also not found in the listed 261 previous variants currently listed at ensembl.org.</p>
</sec>
<sec id="sec3dot2dot3-ijms-20-03358">
<title>3.2.3. Deleterious and Damaging Nature of the Novel <italic>TMEM187</italic>- Variant</title>
<p>Our extensive analyses of this novel variant, as detailed in the Results section, was often determined to be deleterious or damaging. Glutamine, which is a polar amino acid, was changed to histidine and this alters the protein [<xref ref-type="bibr" rid="B43-ijms-20-03358">43</xref>,<xref ref-type="bibr" rid="B44-ijms-20-03358">44</xref>].</p>
</sec>
<sec id="sec3dot2dot4-ijms-20-03358">
<title>3.2.4. TMEM187 Protein Is Expressed in Brain</title>
<p>Like <italic>SYTL4,</italic> the <italic>TMEM187</italic> gene is ubiquitously expressed in all systems including all parts of the brain (<uri xlink:href="www.uniprot.org/uniprot/Q14656">www.uniprot.org/uniprot/Q14656</uri>; <uri xlink:href="www.genecards.org/">www.genecards.org/</uri>).</p>
</sec>
<sec id="sec3dot2dot5-ijms-20-03358">
<title>3.2.5. STRING–Gene Interaction Network Study Reveals Direct Protein–Protein Interactions of the TMEM187 Gene with Several Other Known Autism Genes</title>
<p>Although the novel X-linked <italic>TMEM187</italic> missense gene variant c.708G&gt;T; p.Gln236His found in our high-functioning autism patient is not known as an ASD gene, but analysis of the latest STRING network interactions reveal direct interactions with four known ASD genes, namely <italic>HCFC1</italic>, <italic>TMLHE</italic>, <italic>MECP2</italic>, and <italic>GPHN</italic> (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>) (<xref ref-type="fig" rid="ijms-20-03358-f007">Figure 7</xref>).</p>
</sec>
<sec id="sec3dot2dot6-ijms-20-03358">
<title>3.2.6. Significance of <italic>TMEM187</italic> Protein-Protein Interacting Autism Genes</title>
<p><italic>HCFC1</italic> is a syndromic ASD gene that interacts with <italic>TMEM187</italic>, while <italic>TMLHE, MECP2</italic> and <italic>GPHN</italic> are rare single gene autism genes (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). <italic>HCFC1</italic> is involved in control of the cell cycle with mutations in this X-linked (Xq28) gene associated with intellectual disability [<xref ref-type="bibr" rid="B26-ijms-20-03358">26</xref>]. The two genes (<italic>TMEM187</italic> and <italic>HCFC1</italic>) lie just 2kb apart [<xref ref-type="bibr" rid="B95-ijms-20-03358">95</xref>]. Over expression of <italic>HCFC1</italic> due to a variant is linked to intellectual disability [<xref ref-type="bibr" rid="B26-ijms-20-03358">26</xref>]. A rare mutation in <italic>TMLHE</italic> has been identified with autism (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
<p>The <italic>TMEM187</italic> gene is in linkage with the <italic>MECP2</italic> gene which is a well-known determinant of brain structure, and amino acid variations in the MECP2 protein cause micro-encephalopathy and are also associated with several neurodevelopmental disorders that affect both brain morphology and cognition [<xref ref-type="bibr" rid="B96-ijms-20-03358">96</xref>]. Mutations in this gene underlie Rett syndrome, a well-known autism disorder (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). Rare single gene mutations in the <italic>GPHN</italic> gene are associated with ASD and this gene encodes a neuronal assembly protein that anchors inhibitors of neurotransmitter receptors to postsynaptic cytoskeleton (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
</sec>
<sec id="sec3dot2dot7-ijms-20-03358">
<title>3.2.7. Significance of Other Protein-Protein Interactions of TMEM187</title>
<p>The TMEM187 protein interacts directly with <italic>UBL4A, RBM25,</italic> and <italic>AKAP4</italic> (<xref ref-type="fig" rid="ijms-20-03358-f007">Figure 7</xref>). Though these genes are not known ASD genes, their other transcriptome-wide isoform-level family member genes are known ASD genes: <italic>UBL7</italic>, <italic>RBM27</italic>, <italic>RBM8A</italic>, <italic>RBMS3</italic> and <italic>AKAP9</italic> (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>).</p>
<p>Additionally, the TMEM187 protein directly interacts with the LAGE3 (L Antigen Family Member 3) protein (<xref ref-type="fig" rid="ijms-20-03358-f007">Figure 7</xref>), however, <italic>LAGE3</italic> is not a known ASD gene. It is associated with Galloway-Mowat syndrome 2, an X-linked early-onset nephrotic syndrome associated with microcephaly, central nervous system abnormalities, developmental delay, and a propensity for seizures. Brain anomalies include gyration defects such as lissencephaly, pachygyria, polymicrogyria, and cerebellar hypoplasia. Most patients show facial dysmorphism characterized by a small, narrow forehead, large/floppy ears, deep-set eyes, hypertelorism, and micrognathia (<uri xlink:href="www.uniprot.org/uniprot/Q14657">www.uniprot.org/uniprot/Q14657</uri>).</p>
</sec>
<sec id="sec3dot2dot8-ijms-20-03358">
<title>3.2.8. Other TMEM Proteins Gene Family Members Are Known Autism, Bipolar and Panic Disorder Genes</title>
<p>Other transmembrane proteins gene family members, such as <italic>TMEM231</italic>, are known syndromic autism genes (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>). This gene is associated with two neurological syndromes: Joubert syndrome-20 [MIM:614970] and Meckel syndrome 11 (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>; MIM:615397). Additionally, two other members (TMEM132E and TMEM132D) are known to be associated with bipolar and panic disorders [<xref ref-type="bibr" rid="B97-ijms-20-03358">97</xref>,<xref ref-type="bibr" rid="B98-ijms-20-03358">98</xref>].</p>
</sec>
<sec id="sec3dot2dot9-ijms-20-03358">
<title>3.2.9. X-chromosome Harbors Disproportionately Higher Number of <italic>TMEM187</italic>-Interacting Autism and Nervous System Disorder Genes: Implications for Boys vs Girls Ratio</title>
<p>Except for <italic>GPHN</italic> gene located on chromosome 14, all the other genes (<italic>TMEM187, HCFC1, TMLHE, MECP2, LAGE3</italic> and <italic>SYTL4</italic>) are located exclusively on the long arm of the X-chromosome. The <italic>LAGE3</italic> gene, whose family of genes are clustered together at Xq28, is like that of <italic>TMEM187, HCFC1, TMLHE,</italic> and <italic>MECP2</italic>. SYTL4 is also located on the X-chromosome at q22.1, proximal to the centromere. This augments the assertion that X-chromosome harbors a disproportionately higher number of ASD and nervous system disorder genes [<xref ref-type="bibr" rid="B99-ijms-20-03358">99</xref>], and consequently, disproportionately affects more boys than girls, given that the overall odds-ratio for ASD is increased if the rare hemizygous mutation is on the X-chromosome and X-linked genes expressed in the brain [<xref ref-type="bibr" rid="B41-ijms-20-03358">41</xref>] as is the case in all six of these X-linked genes (<uri xlink:href="www.genecards.org">www.genecards.org</uri>).</p>
</sec>
</sec>
</sec>
<sec id="sec4-ijms-20-03358">
<title>4. Materials and Methods</title>
<sec id="sec4dot1-ijms-20-03358">
<title>4.1. Clinical Report</title>
<p>The 7-year-old male proband was the only child born to healthy young non-consanguineous parents. There was no family history of genetic disorders, malformations, epilepsy, autism, or intellectual disability. Our proband was the product of a 38-week pregnancy to a primigravida mother via an uncomplicated C-section due to a transverse presentation. The Apgar scores were 9 and 9 at 1 and 5 min, respectively. The birth weight was 3600 gm (55th percentile), length was 52 cm (85th percentile), and head circumference was 35 cm (55th percentile).</p>
<p>The proband was evaluated in the Department of Pediatric Neurology, Hospital Universitario Quirón, Madrid, Spain at the age of 4.5 years due to longstanding impairment in social and communicative functioning. Although an early intervention program was established in the first months of life for motor, cognitive, speech development, and social behavior, the proband exhibited mild psychomotor delay during his first years of life. He walked unsupported at 11 months but had significant problems with walking, squatting or dressing at 4.5 years of age. First bi-syllabic babbling occurred at 18 months; at the age of 3 years, he only spoke words without making sentences. His social development was markedly affected; he showed atypical behaviors, refused playing with other children, had a limited amount of interests, and eye contact was minimal.</p>
<p>His weight was 19 kg (65th percentile) and height was 109 cm (65th percentile). He had down-slanting palpebral fissures, mild hypertelorism, thin upper lip, and a pointed chin. Conventional genetic studies (karyotype and array comparative genomic hybridization) showed no abnormalities. The neurological exam was normal. He had impaired social interaction during the examination and lacked eye contact, had peculiar language (echolalias, verbosity, and abnormal pitch), stereotyped mannerisms, and restricted patterns of interest. Brain MRI and sleep video-EEG tests displayed normal results. Cognitive assessment using the Wechsler Preschool and Primary Test of Intelligence-III (WPPSI-III) revealed a verbal and non-verbal IQ at above-average level without significant discrepancies. The Behavior Assessment System for Children (BASC) completed by his parents and preschool teachers revealed significant problems in “social skills,” “adaptability” and “atypicality” domains.</p>
<p>At the age of 6 years, his neurological examination remained normal, but he had an unusually high-pitched voice with stereotyped phrases and echolalia. He tended to perseverate on repetitive interests and activities (chronology of history, borders of countries). His eye contact was inconsistent and poorly integrated with other communicative efforts. He reacted aversely to sensory stimuli (e.g., loud noise, flavors). Autism Spectrum Screening Questionnaire (ASSQ), the Autism Diagnostic Interview-Revised (ADI-R), and the Autism Diagnostic Observation Scale (ADOS, Module 3) were administered. His total score on the ASSQ was 31 and 29 according to the evaluation by the teachers and parents (high-functioning autism cut-off = 22 and 19, respectively). His ADI-R algorithm scores were 15 on the social domain (autism cut-off = 10), 11 on the communication domain for verbal children (autism cut-off = 8), and 5 on the repetitive behavior’s domain (autism cut-off = 3). His total score on the ADOS communication and social algorithm items were 6 and 9 (autism cut-off = 3 and 6, respectively). The clinical and neuropsychological evaluations were consistent with high-functioning autism. The patients allowed for us to undertake research investigations. The study was approved by the local ethics committees on January 7, 2016 and was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice standards. Informed consent was obtained from parents, with the child giving assent.</p>
</sec>
<sec id="sec4dot2-ijms-20-03358">
<title>4.2. Genomic Investigations</title>
<p>Exome sequencing was performed using genomic DNA isolated (MagnaPure, Roche Applied Science, Manheim, Germany) from whole blood from the proband and parents. Libraries were prepared using the Ion AmpliSeq™ Exome Kit (Life Technologies, Carlsbad, California, USA) and quantified by qPCR. The enriched libraries were prepared using Ion Chef™ and sequenced on PI™ Chip in the Ion Proton™ System (Life Technologies) to provide &gt;90% of amplicons covered with at least 20X. Signal processing, base calling, alignment and variant calling were performed on a Proton™ Torrent Server using the Torrent Suite™ Software (v4.4 Life Technologies, Carlsbad, CA, USA). Variants were annotated using Ion Reporter™ Software with the human genome reference assemble GRCh37 (hg19) and pedigree analysis performed using the Genetic Disease Screen (GDS) trio workflow.</p>
<p>Candidate variants were visualized using IGV (Integrative Genomics Viewer, Cambridge, MA, USA) and evaluated based on stringent assessments at both the gene and variant levels, taking into consideration both the patient’s phenotype and the inheritance pattern. Variants in the <italic>SYTL4</italic> and <italic>TMEM187</italic> genes were recognized as probable pathogenic and confirmed by Sanger sequencing. However, due to the lack of cooperation from other family members, additional testing was not available.</p>
</sec>
<sec id="sec4dot3-ijms-20-03358">
<title>4.3. Modeling of Native and R279C Variant for SYTL4 Gene</title>
<p>The theoretical atomic models of native and R279C <italic>SYTL4</italic> were constructed using I-TASSER [<xref ref-type="bibr" rid="B20-ijms-20-03358">20</xref>,<xref ref-type="bibr" rid="B100-ijms-20-03358">100</xref>,<xref ref-type="bibr" rid="B101-ijms-20-03358">101</xref>]. With human SYTL4 sequence (UniProtKB Accession # = Q96C24) as query, multiple sequence-template alignments were initially generated by the meta-threading program LOMETS [<xref ref-type="bibr" rid="B20-ijms-20-03358">20</xref>,<xref ref-type="bibr" rid="B102-ijms-20-03358">102</xref>,<xref ref-type="bibr" rid="B103-ijms-20-03358">103</xref>], followed by generation of the predicted atomic structures. Native SYTL4 matched well with several moderately high-scoring templates corresponding to synaptotagmin family members, with an estimated TM score of 0.5 ± 0.15 and RMSD of 12.2 ± 4.4 Å. The R279C variant also matched to synaptotagmin family member templates, with slightly lower scores, yielding a TM score and RMSD of 0.45 ± 0.15 and 13.5 ± 4.0 Å, respectively.</p>
<p>Both structures were close to the threshold (TM score &gt;0.5) for correct topology. Molecular graphics and analyses were performed with the UCSF Chimera package. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311) [<xref ref-type="bibr" rid="B85-ijms-20-03358">85</xref>].</p>
</sec>
<sec id="sec4dot4-ijms-20-03358">
<title>4.4. MicroRNAs</title>
<p>MicroRNAs (miRNAs / miRs) play a key role in the transcriptional networks of the developing human brain, as regulators of gene expression. Autism spectrum disorder (ASD), being a complex neurodevelopmental disorder, is characterized by multiple deficits in communication, social interaction and behavior [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. Vasu et al. [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] examined the serum expression profiles of 125 neurologically relevant miRNAs expression profiles in 55 individuals with ASD. These neurologically relevant miRNAs represented pathways involved in axon guidance, TGF-beta signaling, MAPK signaling, adherents’ junction, regulation of actin cytoskeleton, oxidative phosphorylation, hedgehog signaling, focal adhesion, mTOR signaling, and Wnt signaling [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>].</p>
<p>Vasu et al. [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] found that only 13 miRNAs (out of the selected 125 miRs; ~10%) were differentially expressed among the 55 ASD individuals compared to the controls in their serum. Of these 13, miR151a-3p, miR181b-5p, miR320a, miR328, miR433, miR489, miR572, and miR663a were downregulated (61.5%), while miR101-3p, miR106b-5p, miR130a-3p, miR195-5p, and miR19b-3p were upregulated (38.5%) [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. Furthermore, of these 13 miRs, only five miRs (38.5%), namely, miR181b-5p, miR320a, miR572, miR130a-3p and miR19b-3p had high values for sensitivity, specificity and area under the curve, thereby showing good predictive power for distinguishing individuals with ASD [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. Therefore, it was decided to screen for the presence of these five miRNAs with good ASD predictive power, namely, miR181b-5p, miR320a, miR572, miR130a-3p and miR19b-3p as well as the other five miRs that were also differentially expressed among the 55 ASD individuals among the 298 validated/predicted microRNA interactions of mouse <italic>Sytl4</italic> gene [<xref ref-type="bibr" rid="B86-ijms-20-03358">86</xref>,<xref ref-type="bibr" rid="B87-ijms-20-03358">87</xref>,<xref ref-type="bibr" rid="B88-ijms-20-03358">88</xref>,<xref ref-type="bibr" rid="B104-ijms-20-03358">104</xref>]. Additionally, we screened for the presence of other significantly ASD-associated miRs from brain-specific micro RNA expression studies by others [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-03358">36</xref>,<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>].</p>
</sec>
</sec>
<sec id="sec5-ijms-20-03358" sec-type="conclusions">
<title>5. Conclusions</title>
<p>1. <italic>TMEM187</italic> as well as <italic>SYTL4</italic> genes are: X-linked and both located on the long arm of the X-chromosome at Xq28 and Xq22.1, respectively;</p>
<p>2. Both <italic>Q236H TMEM187</italic> and R279C SYTL4 gene variants have been predicted to be damaging or deleterious by SIFT, PolyPhen2, MutationTaster, Provean, and LRT variant calling programs;</p>
<p>3. Both <italic>TMEM187</italic> and <italic>SYTL4</italic> mRNAs are found in extracellular vesicles and stimulate target cells to translate into active protein [<xref ref-type="bibr" rid="B17-ijms-20-03358">17</xref>], and the release and uptake of extracellular vesicles in the nervous system and glial cells provides novel mechanisms of transcellular communication [<xref ref-type="bibr" rid="B73-ijms-20-03358">73</xref>];</p>
<p>4. Together, <italic>TMEM187</italic> and <italic>SYTL4</italic> genes directly interact with seven known ASD genes: four and three ASD genes, respectively (<xref ref-type="fig" rid="ijms-20-03358-f004">Figure 4</xref> and <xref ref-type="fig" rid="ijms-20-03358-f007">Figure 7</xref>; <uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>);</p>
<p>5. Another transmembrane protein gene family member, <italic>TMEM231</italic>, is a known syndromic autism gene: <italic>TMEM231</italic> gene is associated with two neurological syndromes: Joubert syndrome-20 [MIM:614970] and Meckel syndrome 11 (<uri xlink:href="https://gene.sfari.org/database/human-gene/">https://gene.sfari.org/database/human-gene/</uri>; MIM:615397);</p>
<p>6. The SYTl4-RAB-binding protein RAB27A is specifically associated with mild cognitive impairment and Alzheimer disease [<xref ref-type="bibr" rid="B52-ijms-20-03358">52</xref>];</p>
<p>7. RAB-binding GTPases play a crucial role in causing diverse patho-physiologies including X- linked mental retardation (intellectual disability) associated with autism, epilepsy, and macrocephaly, suggesting a major role for specific RAB-binding effector proteins, such as SYTL4, and interacting RAB-activating GTPases (RAB GTPases) in the maintenance of normal neuronal function [<xref ref-type="bibr" rid="B51-ijms-20-03358">51</xref>,<xref ref-type="bibr" rid="B59-ijms-20-03358">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-03358">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03358">61</xref>,<xref ref-type="bibr" rid="B64-ijms-20-03358">64</xref>,<xref ref-type="bibr" rid="B65-ijms-20-03358">65</xref>,<xref ref-type="bibr" rid="B66-ijms-20-03358">66</xref>];</p>
<p>8. Two other members of the transmembrane protein gene family, <italic>TMEM132E</italic> and <italic>TMEM132D,</italic> are known to be associated with bipolar and panic disorders, respectively [<xref ref-type="bibr" rid="B97-ijms-20-03358">97</xref>,<xref ref-type="bibr" rid="B98-ijms-20-03358">98</xref>];</p>
<p>9. One of the <italic>TMEM187</italic> genes’ related phenotypes is schizophrenia (GWAS catalog for TMEM187 gene: Gene relation via enhancers containing phenotype SNP: Enhancer ID: GH0XJ153980; <uri xlink:href="https://genecards.weizmann.ac.il/geneloc-bin/display_map.pl?chr_nr=0X&amp;range_type=gh_id&amp;gh_id=GH0XJ153941#GH0XJ153941">https://genecards.weizmann.ac.il/geneloc-bin/display_map.pl?chr_nr=0X&amp;range_type=gh_id&amp;gh_id=GH0XJ153941#GH0XJ153941</uri>). Similarly, our extensive ASD predictive mouse Sytl4-interacting microRNAs study reveals that 50% of the ASD-associated miRs are known to be associated with schizophrenia (<xref ref-type="table" rid="ijms-20-03358-t004">Table 4</xref>);</p>
<p>10. A recent large study of gene expression patterns from postmortem brain tissues found transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, bipolar disorder, panic disorder, and other related neurological disorders [<xref ref-type="bibr" rid="B105-ijms-20-03358">105</xref>], supporting our above findings in <italic>SYTL4</italic> and <italic>TMEM187</italic> gene variants that ASD and schizophrenia share common neurobiological features [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>,<xref ref-type="bibr" rid="B92-ijms-20-03358">92</xref>,<xref ref-type="bibr" rid="B93-ijms-20-03358">93</xref>];</p>
<p><italic>11.</italic> Both <italic>SYTL4</italic> and the <italic>TMM187</italic> genes are ubiquitously expressed, including in the brain [<xref ref-type="bibr" rid="B9-ijms-20-03358">9</xref>,<xref ref-type="bibr" rid="B10-ijms-20-03358">10</xref>,<xref ref-type="bibr" rid="B14-ijms-20-03358">14</xref>] (<uri xlink:href="www.GeneCards.Org">www.GeneCards.Org</uri>; <uri xlink:href="www.Uniprot.Org">www.Uniprot.Org</uri>). The overall odds-ratio for ASD is increased if rare hemizygous mutations on the X-chromosome in male patients are found as these genes have known expression in the brain [<xref ref-type="bibr" rid="B41-ijms-20-03358">41</xref>].</p>
<p>Given the above analytical analyses, there is evidence to support that the missense mutations seen in both the <italic>TMEM187</italic> and <italic>SYTL4</italic> genes, either synergistically or individually, are causal mutations for the high-functioning autism seen in our patient. Consequently, both genes are proposed as novel autism candidate genes.</p>
<p>It is probable that both gene variants synergistically are causative of the high-functioning autism seen in our patient. Oligogenic heterozygosity or involvement of more than one gene observed in patients, suggests a new potential mechanism in the pathogenesis of autism spectrum disorders [<xref ref-type="bibr" rid="B106-ijms-20-03358">106</xref>], further supporting the suggestion that the multifactorial model of ASD risk or monogenic may be too simplistic even for the most penetrant causes of ASD [<xref ref-type="bibr" rid="B107-ijms-20-03358">107</xref>]. Pathogenicity of mutations individually or synergistically would require biological assays, such as in-vivo models, for study. Meanwhile, publications of similar findings by others in the study of autism involving either of these two gene variants would lend credence to our findings and assertions.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Waheeda Hossain in the Departments of Psychiatry &amp; Behavioral Sciences, University of Kansas Medical Center (Kansas City, KS., 66160 USA) reviewed and edited the manuscript. Charlotte Iannachi in the Departments of Psychiatry &amp; Behavioral Sciences, University of Kansas Medical Center rendered valuable help with the manuscript processing. Mark Grubb (Kansas City, MO. 64171 USA) and Azhar Mohammed (Falls Church, VA. 22044 USA) assisted in the production of figures. We acknowledge the seminal contribution of the proband’s family to this study.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>The manuscript was conceived and entirely drafted by S.K.R., including the title, figures, tables, microRNA study, interpretation, discussion, conclusion, materials and methods, and references. M.G.B. reviewed, contributed and edited the entire manuscript. The clinical studies were conducted by A.F.-J., Neuro-pediatrician at the Department of Pediatric Neurology, Hospital Universitario Quirón, Madrid, Spain. The clinical case report was by A.F.-J. The genomic studies were conducted by S.Á., at the Genomics and Medicine, NIM Genetics, Madrid, Spain. The theoretical 3D structural modeling of native SYTL4 as well as the analysis of predicted atomic threading models of the mutant and native SYTL4 proteins, and the interpretation thereof was by O.W.N., at the Department of Biochemistry &amp; Molecular Biology, University of Kansas Medical Center. Kansas City, USA. S.K.R. was granted permissions to reproduce in this manuscript the following: (1) the gene interaction STRING networks (by M.S., Head of GeneCards Development, Weizmann Institute of Science, Israel (<uri xlink:href="www.GeneCards.Org">www.GeneCards.Org</uri> &amp; STRING Consortium)) and (2) the SYTL4 protein secondary structure graphics by E.G., SIB Swiss Institute of Bioinformatics, Geneva, Switzerland (UniProtKB/Swiss-Prot; <uri>WWW.Uniprot.Org</uri>; Q96C24).</p>
</notes>
<notes>
<title>Funding</title>
<p>Owen W. Nadeau acknowledges the research funding support for this project from NIH grant # DK32953. Merlin G. Butler acknowledges National Institute of Child Health and Human Development (NICHD) grant HD02528.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-03358">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shashi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>McConkie-Rosell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rosell</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schoch</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vellore</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Need</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>The utility of the traditional medical genetic diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders</article-title>
<source/>Genet. Med.
          <year>2014</year>
<volume>16</volume>
<fpage>176</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2013.99</pub-id>
<pub-id pub-id-type="pmid">23928913</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-03358">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LePichon</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Soden</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>The future of next-generation sequencing in neurology</article-title>
<source/>JAMA Neurol.
          <year>2015</year>
<volume>72</volume>
<fpage>971</fpage>
<lpage>972</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2015.1076</pub-id>
<pub-id pub-id-type="pmid">26148113</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-03358">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ankala</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wilcox</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: Single-gene, gene panel, or exome/genome sequencing</article-title>
<source/>Genet. Med.
          <year>2015</year>
<volume>17</volume>
<fpage>444</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2014.122</pub-id>
<pub-id pub-id-type="pmid">25232854</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-03358">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Deriziotis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karakoc</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mackenzie</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations</article-title>
<source/>Nat. Genet.
          <year>2011</year>
<volume>43</volume>
<fpage>585</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="doi">10.1038/ng.835</pub-id>
<pub-id pub-id-type="pmid">21572417</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-03358">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon-Salazar</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Silhavy</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Udpa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schroth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bielas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Olvera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bafna</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zaki</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Abdel-Salam</surname>
<given-names>G.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing can improve diagnosis and alter patient management</article-title>
<source/>Sci. Transl. Med.
          <year>2012</year>
<volume>4</volume>
<fpage>138ra78</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3003544</pub-id>
<pub-id pub-id-type="pmid">22700954</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-03358">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Murtha</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Murdoch</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Raubeson</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Willsey</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Ercan-Sencicek</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>DiLullo</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Parikshak</surname>
<given-names>N.N.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>J.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations revealed by whole-exome sequencing are strongly associated with autism</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>237</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1038/nature10945</pub-id>
<pub-id pub-id-type="pmid">22495306</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-03358">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Chahrour</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Coulter</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Jiralerspong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Okamura-Ikeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ataman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schmitz-Abe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Harmin</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Adli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>A.N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Using whole-exome sequencing to identify inherited causes of autism</article-title>
<source/>Neuron
          <year>2013</year>
<volume>77</volume>
<fpage>259</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.11.002</pub-id>
<pub-id pub-id-type="pmid">23352163</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-03358">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasieva</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Cetiner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schumann</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Bubb</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function in Neurons and Cognition</article-title>
<source/>arXiv
          <year>2016</year>
<pub-id pub-id-type="arxiv">1602.07642v2</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-03358">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Coats</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>O.M.</given-names>
</name>
<name>
<surname>Alvarado</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>N.M.</given-names>
</name>
</person-group>
<article-title>Modular genetic control of sexually dimorphic behaviors</article-title>
<source/>Cell
          <year>2012</year>
<volume>48</volume>
<fpage>596</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.12.018</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-03358">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lebow</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Overshadowed by the amygdala: The bed nucleus of the stria terminalis emerges as key to psychiatric disorders</article-title>
<source/>Mol. Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>450</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2016.1</pub-id>
<pub-id pub-id-type="pmid">26878891</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-03358">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerman</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bunney</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Schatzberg</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Barchas</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Akil</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Evidence for transcriptional factor dysregulation in the dorsal raphe nucleus of patients with major depressive disorder</article-title>
<source/>Front. Neurosci.
          <year>2012</year>
<volume>6</volume>
<fpage>135</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2012.00135</pub-id>
<pub-id pub-id-type="pmid">23087602</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-03358">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szego</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Janáky</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Szabó</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Csorba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kompagne</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lévay</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Simor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Juhász</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kékesi</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2010</year>
<volume>20</volume>
<fpage>96</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2009.11.003</pub-id>
<pub-id pub-id-type="pmid">20015620</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-03358">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ishizaki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gomi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The Rab27a effector exophilin7 promotes fusion of secretory granules that have not been docked to the plasma membrane</article-title>
<source/>Mol. Biol. Cell
          <year>2013</year>
<volume>24</volume>
<fpage>319</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e12-04-0265</pub-id>
<pub-id pub-id-type="pmid">23223571</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-03358">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Modular genetic control of innate behaviors</article-title>
<source/>Bioessays
          <year>2013</year>
<volume>35</volume>
<fpage>421</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1002/bies.201200167</pub-id>
<pub-id pub-id-type="pmid">23483537</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-03358">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Rafi</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Stephan</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Whole exome sequencing in females with autism implicates novel and candidate genes</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>1312</fpage>
<lpage>1335</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16011312</pub-id>
<pub-id pub-id-type="pmid">25574603</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-03358">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Itohara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Rab27b is expressed in a wide range of exocytic cells and involved in the delivery of secretory granules near the plasma membrane</article-title>
<source/>Mol. Biol. Cell
          <year>2007</year>
<volume>18</volume>
<fpage>4377</fpage>
<lpage>4386</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e07-05-0409</pub-id>
<pub-id pub-id-type="pmid">17761531</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-03358">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boivin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Deschamps-Francoeur</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Protein coding genes as hosts for noncoding RNA expression</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2018</year>
<volume>75</volume>
<fpage>3</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2017.08.016</pub-id>
<pub-id pub-id-type="pmid">28811264</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-03358">
<label>18.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Bonanno</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bain</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wasserman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sauder</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Burley</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Almo</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<source/>Protein Data Bank in Europe (PDBe) ID: 3fdw: Crystal Structure of a C2 Domain from Human Synaptotagmin-Like Protein 4
          <publisher-name>New York SGX Research Center for Structural Genomics (NYSGXRC)</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>2008</year>
</element-citation>
</ref>
<ref id="B19-ijms-20-03358">
<label>19.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koshiba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kigawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Protein Data Bank (PDB) ID: 2CSZ: Solution Structure of the RING Domain of the Synaptotagmin-Like Protein 4</article-title>
<publisher-name>RIKEN Structural Genomics/Proteomics Initiative (RSGI)</publisher-name>
<year>2005</year>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/Structure/pdb/2CSZ">https://www.ncbi.nlm.nih.gov/Structure/pdb/2CSZ</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2018-07-08">(accessed on 8 July 2018)</date-in-citation>
</element-citation>
</ref>
<ref id="B20-ijms-20-03358">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>I-TASSER server for protein 3D structure prediction</article-title>
<source/>BMC Bioinform.
          <year>2008</year>
<volume>9</volume>
<elocation-id>40</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2105-9-40</pub-id>
<pub-id pub-id-type="pmid">18215316</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-03358">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berman</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Westbrook</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gilliland</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Weissig</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shindyalov</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Bourne</surname>
<given-names>P.E.</given-names>
</name>
</person-group>
<article-title>The protein data bank</article-title>
<source/>Nucleic Acids Res.
          <year>2000</year>
<volume>28</volume>
<fpage>235</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id>
<pub-id pub-id-type="pmid">10592235</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-03358">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuson</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Montes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>R.B.</given-names>
</name>
</person-group>
<article-title>Structure of human synaptotagmin 1 C2AB in the absence of Ca2+ reveals a novel domain association</article-title>
<source/>Biochemistry
          <year>2007</year>
<volume>46</volume>
<fpage>13041</fpage>
<lpage>13048</lpage>
<pub-id pub-id-type="doi">10.1021/bi701651k</pub-id>
<pub-id pub-id-type="pmid">17956130</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-03358">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schauder</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Saheki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Narayanaswamy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Torta</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wenk</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>De Camilli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Reinisch</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>Structure of a lipid-bound extended synaptotagmin indicates a role in lipid transfer</article-title>
<source/>Nature
          <year>2014</year>
<volume>510</volume>
<fpage>552</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1038/nature13269</pub-id>
<pub-id pub-id-type="pmid">24847877</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-03358">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donald</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Kulp</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>DeGrado</surname>
<given-names>W.F.</given-names>
</name>
</person-group>
<article-title>Salt bridges: Geometrically specific, designable interactions</article-title>
<source/>Proteins
          <year>2011</year>
<volume>79</volume>
<fpage>898</fpage>
<lpage>915</lpage>
<pub-id pub-id-type="doi">10.1002/prot.22927</pub-id>
<pub-id pub-id-type="pmid">21287621</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-03358">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregoret</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Rade</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Fletterick</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>F.E.</given-names>
</name>
</person-group>
<article-title>Hydrogen bonds involving sulfur atoms in proteins</article-title>
<source/>Proteins
          <year>1991</year>
<volume>9</volume>
<fpage>99</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1002/prot.340090204</pub-id>
<pub-id pub-id-type="pmid">1755867</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-03358">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Franceschini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wyder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Forslund</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huerta-Cepas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Simonovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tsafou</surname>
<given-names>K.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STRING v10: Protein-protein interaction networks, integrated over the tree of life</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>D447</fpage>
<lpage>D452</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku1003</pub-id>
<pub-id pub-id-type="pmid">25352553</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-03358">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haraguchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okajima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iwamoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fukumoto</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>b-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve</article-title>
<source/>J. Biol. Chem.
          <year>2002</year>
<volume>277</volume>
<fpage>1633</fpage>
<lpage>1636</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.C100395200</pub-id>
<pub-id pub-id-type="pmid">11682464</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-03358">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamberger</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nikanorova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Accorsi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Angriman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baier</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Benkel-Herrenbrueck</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Benoit</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Budetta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Caliebe</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STXBP1 Encephalopathy: A neurodevelopmental disorder including epilepsy</article-title>
<source/>Neurology
          <year>2016</year>
<volume>86</volume>
<fpage>954</fpage>
<lpage>962</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000002457</pub-id>
<pub-id pub-id-type="pmid">26865513</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-03358">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Söllner</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Whiteheart</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Scheller</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion</article-title>
<source/>Cell
          <year>1993</year>
<volume>75</volume>
<fpage>409</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(93)90376-2</pub-id>
<pub-id pub-id-type="pmid">8221884</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-03358">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neves</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Ram</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Iyengar</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>G protein pathways</article-title>
<source/>Science
          <year>2002</year>
<volume>296</volume>
<fpage>1636</fpage>
<lpage>1639</lpage>
<pub-id pub-id-type="doi">10.1126/science.1071550</pub-id>
<pub-id pub-id-type="pmid">12040175</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-03358">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapoport</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chavez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greenstein</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Addington</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gogtay</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorders and childhood-onset schizophrenia: Clinical and biological contributions to a relation revisited</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2009</year>
<volume>48</volume>
<fpage>10</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1097/CHI.0b013e31818b1c63</pub-id>
<pub-id pub-id-type="pmid">19218893</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-03358">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beveridge</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>MicroRNA dysregulation in schizophrenia</article-title>
<source/>Neurobiol. Dis.
          <year>2012</year>
<volume>46</volume>
<fpage>263</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2011.12.029</pub-id>
<pub-id pub-id-type="pmid">22207190</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-03358">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeshan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Aberrant expression of serum miRNAs in schizophrenia</article-title>
<source/>J. Psychiatr. Res.
          <year>2012</year>
<volume>46</volume>
<fpage>198</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2011.09.010</pub-id>
<pub-id pub-id-type="pmid">22094284</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-03358">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Anitha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thanseem</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wakuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsujii</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum microRNA profiles in children with autism</article-title>
<source/>Mol. Autism
          <year>2014</year>
<volume>5</volume>
<fpage>40</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-5-40</pub-id>
<pub-id pub-id-type="pmid">25126405</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-03358">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abu-Elneel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gazzaniga</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Lao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kosik</surname>
<given-names>K.S.</given-names>
</name>
</person-group>
<article-title>Heterogeneous dysregulation of microRNAs across the autism spectrum</article-title>
<source/>Neurogenetics
          <year>2008</year>
<volume>9</volume>
<fpage>153</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-008-0133-5</pub-id>
<pub-id pub-id-type="pmid">18563458</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-03358">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghahramani Seno</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gwadry</surname>
<given-names>F.G.</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Casallo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Gene and miRNA expression profiles in autism spectrum disorders</article-title>
<source/>Brain Res.
          <year>2011</year>
<volume>1380</volume>
<fpage>85</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.09.046</pub-id>
<pub-id pub-id-type="pmid">20868653</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-03358">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamova</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ander</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Barger</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>F.R.</given-names>
</name>
<name>
<surname>Schumann</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Specific regional and age-related small noncoding RNA expression patterns within superior temporal gyrus of typical human brains are less distinct in autism brains</article-title>
<source/>J. Child Neurol.
          <year>2015</year>
<volume>30</volume>
<fpage>1930</fpage>
<lpage>1946</lpage>
<pub-id pub-id-type="doi">10.1177/0883073815602067</pub-id>
<pub-id pub-id-type="pmid">26350727</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-03358">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anney</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Klei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bacchelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bolshakova</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bölte</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Bourgeron</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Individual common variants exert weak effects on the risk for autism spectrum disorders</article-title>
<source/>Hum. Mol. Genet.
          <year>2012</year>
<volume>21</volume>
<fpage>4781</fpage>
<lpage>4792</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds301</pub-id>
<pub-id pub-id-type="pmid">22843504</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-03358">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Murtha</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Hus</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Willsey</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Moreno-De-Luca</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Fombonne</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common genetic variants, acting additively, are a major source of risk for autism</article-title>
<source/>Mol. Autism
          <year>2012</year>
<volume>3</volume>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-3-9</pub-id>
<pub-id pub-id-type="pmid">23067556</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-03358">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Parikshak</surname>
<given-names>N.N.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Rare inherited variation in autism: Beginning to see the forest</article-title>
<source/>Neuron
          <year>2013</year>
<volume>77</volume>
<fpage>209</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.01.010</pub-id>
<pub-id pub-id-type="pmid">23352155</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-03358">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crestani</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>F.V.</given-names>
</name>
<name>
<surname>Resstel</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Correa</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Mechanisms in the bed nucleus of the stria terminalis involved in control of autonomic and neuroendocrine functions: A review</article-title>
<source/>Curr. Neuropharmacol.
          <year>2013</year>
<volume>11</volume>
<fpage>141</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X11311020002</pub-id>
<pub-id pub-id-type="pmid">23997750</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-03358">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopes</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Burgoyne</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Ojarikre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sargent</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Amorim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Affara</surname>
<given-names>N.A.</given-names>
</name>
</person-group>
<article-title>Transcriptional changes in response to X chromosome dosage in the mouse: Implications for X inactivation and the molecular basis of Turner Syndrome</article-title>
<source/>BMC Genom.
          <year>2010</year>
<volume>11</volume>
<elocation-id>82</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2164-11-82</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-03358">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vitkup</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>The amino-acid mutational spectrum of human genetic disease</article-title>
<source/>Genome Biol.
          <year>2003</year>
<volume>4</volume>
<fpage>R72</fpage>
<pub-id pub-id-type="doi">10.1186/gb-2003-4-11-r72</pub-id>
<pub-id pub-id-type="pmid">14611658</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-03358">
<label>44.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Betts</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>R.B.</given-names>
</name>
</person-group>
<article-title>Amino acid properties and consequences of substitutions</article-title>
<source/>Bioinformatics for Geneticists
          <person-group person-group-type="editor">
<name>
<surname>Barnes</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>I.C.</given-names>
</name>
</person-group>
<publisher-name>John Wiley &amp; Sons</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>2003</year>
</element-citation>
</ref>
<ref id="B45-ijms-20-03358">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vihinen</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Spectrum of disease-causing mutations in protein secondary structures</article-title>
<source/>BMC Struct. Biol.
          <year>2007</year>
<volume>7</volume>
<elocation-id>56</elocation-id>
<pub-id pub-id-type="doi">10.1186/1472-6807-7-56</pub-id>
<pub-id pub-id-type="pmid">17727703</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-20-03358">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poussu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vihinen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Paulin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Savilahti</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Probing the alpha-complementing domain of E. coli beta-galactosidase with use of an insertional pentapeptide mutagenesis strategy based on Mu in vitro DNA transposition</article-title>
<source/>Proteins
          <year>2004</year>
<volume>54</volume>
<fpage>681</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="doi">10.1002/prot.10467</pub-id>
<pub-id pub-id-type="pmid">14997564</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-03358">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vihinen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vetri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Maniar</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Ochs</surname>
<given-names>H.D.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Vorechovský</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Notarangelo</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sowadski</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural basis for chromosome X-linked agammaglobulinemia: A tyrosine kinase disease</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1994</year>
<volume>91</volume>
<fpage>12803</fpage>
<lpage>12807</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.91.26.12803</pub-id>
<pub-id pub-id-type="pmid">7809124</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-03358">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Moult</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Loss of protein structure stability as a major causative factor in monogenic disease</article-title>
<source/>J. Mol. Biol.
          <year>2005</year>
<volume>353</volume>
<fpage>459</fpage>
<lpage>473</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2005.08.020</pub-id>
<pub-id pub-id-type="pmid">16169011</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-03358">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rong</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Vihinen</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Structural basis of Wiskott-Aldrich syndrome causing mutations in the WH1 domain</article-title>
<source/>J. Mol. Med. (Berl.)
          <year>2000</year>
<volume>78</volume>
<fpage>530</fpage>
<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1007/s001090000136</pub-id>
<pub-id pub-id-type="pmid">11140379</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-03358">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lappalainen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Vihinen</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Structural basis of ICF-causing mutations in the methyltransferase domain of DNMT3B</article-title>
<source/>Protein Eng.
          <year>2002</year>
<volume>15</volume>
<fpage>1005</fpage>
<lpage>1014</lpage>
<pub-id pub-id-type="doi">10.1093/protein/15.12.1005</pub-id>
<pub-id pub-id-type="pmid">12601140</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-03358">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strom</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hume</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Tarafder</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Barkagianni</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Seabra</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>A family of Rab27-binding proteins. Melanophilin links Rab27a and myosin Va function in melanosome transport</article-title>
<source/>J. Biol. Chem.
          <year>2002</year>
<volume>277</volume>
<fpage>25423</fpage>
<lpage>25430</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M202574200</pub-id>
<pub-id pub-id-type="pmid">11980908</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-03358">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mufson</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Counts</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Ginsberg</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer’s disease</article-title>
<source/>Neurochem. Res.
          <year>2002</year>
<volume>27</volume>
<fpage>1035</fpage>
<lpage>1048</lpage>
<pub-id pub-id-type="doi">10.1023/A:1020952704398</pub-id>
<pub-id pub-id-type="pmid">12462403</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-03358">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aravind</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Identification of novel families and classification of the C2 domain superfamily elucidate the origin and evolution of membrane targeting activities in eukaryotes</article-title>
<source/>Gene
          <year>2010</year>
<volume>469</volume>
<fpage>18</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2010.08.006</pub-id>
<pub-id pub-id-type="pmid">20713135</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-03358">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyakhova</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>The C2 domains of granuphilin are high-affinity sensors for plasma membrane lipids</article-title>
<source/>Chem. Phys. Lipids
          <year>2014</year>
<volume>182</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.chemphyslip.2013.10.009</pub-id>
<pub-id pub-id-type="pmid">24184645</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-20-03358">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dephoure</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Villén</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Beausoleil</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bakalarski</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Elledge</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Gygi</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>A quantitative atlas of mitotic phosphorylation</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2008</year>
<volume>105</volume>
<fpage>10762</fpage>
<lpage>10767</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0805139105</pub-id>
<pub-id pub-id-type="pmid">18669648</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-03358">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome</article-title>
<source/>J. Proteom.
          <year>2014</year>
<volume>96</volume>
<fpage>253</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1016/j.jprot.2013.11.014</pub-id>
<pub-id pub-id-type="pmid">24275569</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-20-03358">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>D’Souza</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Tyanova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schaab</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wiśniewski</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling</article-title>
<source/>Cell Rep.
          <year>2014</year>
<volume>8</volume>
<fpage>1583</fpage>
<lpage>1594</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.036</pub-id>
<pub-id pub-id-type="pmid">25159151</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-03358">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musafia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Buchner</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Arad</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Complex salt bridges in proteins: Statistical analysis of structure and function</article-title>
<source/>J. Mol. Biol.
          <year>1995</year>
<volume>254</volume>
<fpage>761</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="doi">10.1006/jmbi.1995.0653</pub-id>
<pub-id pub-id-type="pmid">7500348</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-03358">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>G.B.</given-names>
</name>
</person-group>
<article-title>Rab GTPases implicated in inherited and acquired disorders</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2010</year>
<volume>22</volume>
<fpage>57</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2010.12.005</pub-id>
<pub-id pub-id-type="pmid">21147240</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-03358">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stenmark</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Cellular functions of Rab GTPases at a glance</article-title>
<source/>J. Cell Sci.
          <year>2015</year>
<volume>128</volume>
<fpage>3171</fpage>
<lpage>3176</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.166074</pub-id>
<pub-id pub-id-type="pmid">26272922</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-20-03358">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zerial</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Rab proteins as membrane organizers</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2001</year>
<volume>2</volume>
<fpage>107</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1038/35052055</pub-id>
<pub-id pub-id-type="pmid">11252952</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-03358">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukuda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kanno</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Analysis of the role of Rab27 effector Slp4-a/Granuphilin-a in dense-core vesicle exocytosis</article-title>
<source/>Methods Enzymol.
          <year>2005</year>
<volume>403</volume>
<fpage>445</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="pmid">16473610</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-03358">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gomi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Torii</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Functional analysis of Rab27a effector granuphilin in insulin exocytosis</article-title>
<source/>Methods Enzymol.
          <year>2005</year>
<volume>403</volume>
<fpage>216</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">16473589</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-03358">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chavas</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Ihara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawasaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Torii</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Uejima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wakatsuki</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Elucidation of Rab27 recruitment by its effectors: Structure of Rab27a bound to Exophilin4/Slp2-a</article-title>
<source/>Structure
          <year>2008</year>
<volume>16</volume>
<fpage>1468</fpage>
<lpage>1477</lpage>
<pub-id pub-id-type="doi">10.1016/j.str.2008.07.015</pub-id>
<pub-id pub-id-type="pmid">18940603</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-03358">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krzewski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cullinane</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Evidence for defective Rab GTPase-dependent cargo traffic in immune disorders</article-title>
<source/>Exp. Cell Res.
          <year>2013</year>
<volume>319</volume>
<fpage>2360</fpage>
<lpage>2367</lpage>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2013.06.012</pub-id>
<pub-id pub-id-type="pmid">23810987</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-03358">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannandrea</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mignogna</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Sirri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carrabino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D’Elia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vecellio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cogliati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Larizza</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly</article-title>
<source/>Am. J. Hum. Genet.
          <year>2010</year>
<volume>86</volume>
<fpage>185</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2010.01.011</pub-id>
<pub-id pub-id-type="pmid">20159109</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-03358">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goitre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Trapani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Trabalzini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Retta</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>The Ras superfamily of small GTPases: The unlocked secrets</article-title>
<source/>Methods Mol. Biol.
          <year>2014</year>
<volume>1120</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">24470015</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-03358">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>N.M.</given-names>
</name>
</person-group>
<article-title>Representing sex in the brain, one module at a time</article-title>
<source/>Neuron
          <year>2014</year>
<volume>8</volume>
<fpage>261</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2014.03.029</pub-id>
<pub-id pub-id-type="pmid">24742456</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-03358">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Beam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Agniel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Eran</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Manrai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Spettell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mandl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>S.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of Sex with Recurrence of Autism Spectrum Disorder among Siblings</article-title>
<source/>JAMA Pediatr.
          <year>2017</year>
<volume>171</volume>
<fpage>1107</fpage>
<lpage>1112</lpage>
<pub-id pub-id-type="doi">10.1001/jamapediatrics.2017.2832</pub-id>
<pub-id pub-id-type="pmid">28973142</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-03358">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durdiakova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Warrier</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Banerjee-Basu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>STX1A and Asperger syndrome: A replication study</article-title>
<source/>Mol. Autism
          <year>2014</year>
<volume>5</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-5-14</pub-id>
<pub-id pub-id-type="pmid">24548729</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-03358">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halladay</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Constantino</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Messinger</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pelphrey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>A.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sex and gender differences in autism spectrum disorder: Summarizing evidence gaps and identifying emerging areas of priority</article-title>
<source/>Mol. Autism
          <year>2015</year>
<volume>6</volume>
<fpage>36</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-015-0019-y</pub-id>
<pub-id pub-id-type="pmid">26075049</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-03358">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mizutani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Itohara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Granuphilin molecularly docks insulin granules to the fusion machinery</article-title>
<source/>J. Cell Biol.
          <year>2005</year>
<volume>171</volume>
<fpage>99</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200505179</pub-id>
<pub-id pub-id-type="pmid">16216924</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-03358">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Budnik</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ruiz-Cañada</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wendler</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Extracellular vesicles round off communication in the nervous system</article-title>
<source/>Nat. Rev.
          <year>2016</year>
<volume>17</volume>
<fpage>160</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1038/nrn.2015.29</pub-id>
<pub-id pub-id-type="pmid">26891626</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-03358">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Breevoort</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Snijders</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Hellen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Weckhuysen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Hooren</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Eikenboom</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valentijn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fernandez-Borja</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ceulemans</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>De Jonghe</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STXBP1 promotes Weibel-Palade body exocytosis through its interaction with the Rab27A effector Slp4-a</article-title>
<source/>Blood
          <year>2014</year>
<volume>123</volume>
<fpage>3185</fpage>
<lpage>3194</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2013-10-535831</pub-id>
<pub-id pub-id-type="pmid">24700782</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-03358">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Thiruvahindrapuram</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tammimies</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hoang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chrysler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nalpathamkalam</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pellecchia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-genome sequencing of quartet families with autism spectrum disorder</article-title>
<source/>Nat. Med.
          <year>2015</year>
<volume>21</volume>
<fpage>185</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1038/nm.3792</pub-id>
<pub-id pub-id-type="pmid">25621899</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-03358">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franceschini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>von Mering</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>SVD-phy: Improved prediction of protein functional associations through singular value decomposition of phylogenetic profiles</article-title>
<source/>Bioinformatics
          <year>2016</year>
<volume>32</volume>
<fpage>1085</fpage>
<lpage>1087</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btv696</pub-id>
<pub-id pub-id-type="pmid">26614125</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-03358">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braida</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Guerini</surname>
<given-names>F.R.</given-names>
</name>
<name>
<surname>Ponzoni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Corradini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>De Astis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pattini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bolognesi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benfante</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fornasari</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chiappedi</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between SNAP-25 gene polymorphisms and cognition in autism: Functional consequences and potential therapeutic strategies</article-title>
<source/>Transl. Psychiatry
          <year>2015</year>
<volume>5</volume>
<fpage>e500</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2014.136</pub-id>
<pub-id pub-id-type="pmid">25629685</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-03358">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Rho</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.K.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells</article-title>
<source/>BMC Genom.
          <year>2009</year>
<volume>10</volume>
<elocation-id>556</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2164-10-556</pub-id>
<pub-id pub-id-type="pmid">19930720</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-03358">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waites</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Presynaptic function in health and disease</article-title>
<source/>Trends Neurosci.
          <year>2011</year>
<volume>34</volume>
<fpage>326</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2011.03.004</pub-id>
<pub-id pub-id-type="pmid">21596448</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-03358">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Grozeva</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>van Kogelenberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hurles</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Baldeweg</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a human synaptotagmin-1 mutation that perturbs synaptic vesicle cycling</article-title>
<source/>J. Clin. Investig.
          <year>2015</year>
<volume>125</volume>
<fpage>1670</fpage>
<lpage>1678</lpage>
<pub-id pub-id-type="doi">10.1172/JCI79765</pub-id>
<pub-id pub-id-type="pmid">25705886</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-03358">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geppert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Goda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rosahl</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>T.C.</given-names>
</name>
</person-group>
<article-title>Synaptotagmin I: A major Ca2+ sensor for transmitter release at a central synapse</article-title>
<source/>Cell
          <year>1994</year>
<volume>79</volume>
<fpage>717</fpage>
<lpage>727</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(94)90556-8</pub-id>
<pub-id pub-id-type="pmid">7954835</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-03358">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>E.R.</given-names>
</name>
</person-group>
<article-title>C2A activates a cryptic Ca (2+)-triggered membrane penetration activity within the C2B domain of synaptotagmin I</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2002</year>
<volume>99</volume>
<fpage>1665</fpage>
<lpage>1670</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.032541099</pub-id>
<pub-id pub-id-type="pmid">11805296</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-03358">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities</article-title>
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2012</year>
<volume>4</volume>
<fpage>a009886</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a009886</pub-id>
<pub-id pub-id-type="pmid">22258914</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-03358">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacaj</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Morishita</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>T.C.</given-names>
</name>
</person-group>
<article-title>Synaptotagmin-1 and synaptotagmin-7 trigger synchronous and asynchronous phases of neurotransmitter release</article-title>
<source/>Neuron
          <year>2013</year>
<volume>80</volume>
<fpage>947</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.10.026</pub-id>
<pub-id pub-id-type="pmid">24267651</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-03358">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Goddard</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Couch</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Ferrin</surname>
<given-names>T.E.</given-names>
</name>
</person-group>
<article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title>
<source/>J. Comput. Chem.
          <year>2004</year>
<volume>25</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
<pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id>
<pub-id pub-id-type="pmid">15264254</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-03358">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plaisance</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Abderrahmani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Perret-Menoud</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jacquemin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lemaigre</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Regazzi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells</article-title>
<source/>J. Biol. Chem.
          <year>2006</year>
<volume>281</volume>
<fpage>26932</fpage>
<lpage>26942</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M601225200</pub-id>
<pub-id pub-id-type="pmid">16831872</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-03358">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rolland</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Taşan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Charloteaux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pevzner</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sahni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lemmens</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fontanillo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mosca</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A proteome-scale map of the human interactome network</article-title>
<source/>Cell
          <year>2014</year>
<volume>159</volume>
<fpage>1212</fpage>
<lpage>1226</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2014.10.050</pub-id>
<pub-id pub-id-type="pmid">25416956</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-03358">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eppig</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Blake</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Bult</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Kadin</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Mouse Genome Database Group. The mouse genome database (MGD): Facilitating mouse as a model for human biology and disease</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>D726</fpage>
<lpage>D736</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku967</pub-id>
<pub-id pub-id-type="pmid">25348401</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-03358">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MiRNA-320 in the human follicular fluid-development in vitro</article-title>
<source/>Sci. Rep.
          <year>2015</year>
<volume>5</volume>
<fpage>8689</fpage>
<pub-id pub-id-type="doi">10.1038/srep08689</pub-id>
<pub-id pub-id-type="pmid">25732513</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-03358">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prajapati</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kumari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mohindar Singh Singal</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Seth</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Novel insights into role of miR-320a-VDAC1 axis in astrocyte-mediated neuronal damage in neuroAIDS</article-title>
<source/>Glia
          <year>2017</year>
<volume>65</volume>
<fpage>250</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1002/glia.23089</pub-id>
<pub-id pub-id-type="pmid">27761954</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-03358">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z.M.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A preliminary analysis of association between the downregulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment</article-title>
<source/>J. Psychiatr. Res.
          <year>2014</year>
<volume>54</volume>
<fpage>134</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2014.03.008</pub-id>
<pub-id pub-id-type="pmid">24694668</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-03358">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khanzada</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>GeneAnalytics pathway analysis and genetic overlap among autism spectrum disorder, bipolar disorder and schizophrenia</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>527</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18030527</pub-id>
<pub-id pub-id-type="pmid">28264500</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-20-03358">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sundararajan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases</article-title>
<source/>Gene
          <year>2018</year>
<volume>641</volume>
<fpage>25</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2017.10.035</pub-id>
<pub-id pub-id-type="pmid">29032150</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-20-03358">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mor</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nardone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sams</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Hypomethylation of miR-142 promoter and upregulation of microRNAs that target the oxytocin receptor gene in the autism prefrontal cortex</article-title>
<source/>Mol. Autism
          <year>2015</year>
<volume>6</volume>
<fpage>46</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-015-0040-1</pub-id>
<pub-id pub-id-type="pmid">26273428</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-20-03358">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frattini</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Zucchi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Patrosso</surname>
<given-names>C.P.</given-names>
</name>
</person-group>
<article-title>Characterization sequence/EST database screening</article-title>
<source/>Genomics
          <year>1996</year>
<volume>34</volume>
<fpage>323</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="pmid">8786131</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-20-03358">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joyner</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Cooper Roddey</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bloss</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Bakken</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Rimol</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Melle</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Agartz</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Djurovic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Topol</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Schork</surname>
<given-names>N.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>15483</fpage>
<lpage>15488</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0901866106</pub-id>
<pub-id pub-id-type="pmid">19717458</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-20-03358">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sklar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smoller</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Perlis</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Chambert</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nimgaonkar</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>McQueen</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-genome association study of bipolar disorder</article-title>
<source/>Mol. Psychiatry
          <year>2008</year>
<volume>13</volume>
<fpage>558</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4002151</pub-id>
<pub-id pub-id-type="pmid">18317468</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-20-03358">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erhardt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Akula</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schumacher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Czamara</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Karbalai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Müller-Myhsok</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mors</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Borglum</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Woldbye</surname>
<given-names>D.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Replication and meta-analysis of TMEM132D gene variants in panic disorder</article-title>
<source/>Transl. Psychiatry
          <year>2012</year>
<volume>2</volume>
<fpage>e156</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2012.85</pub-id>
<pub-id pub-id-type="pmid">22948381</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-20-03358">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Rafi</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>High-resolution chromosome ideogram representation of currently recognized genes for autism spectrum disorders</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>6464</fpage>
<lpage>6495</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16036464</pub-id>
<pub-id pub-id-type="pmid">25803107</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-20-03358">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kucukural</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>I-TASSER: A unified platform for automated protein structure and function prediction</article-title>
<source/>Nat. Protoc.
          <year>2010</year>
<volume>5</volume>
<fpage>725</fpage>
<lpage>738</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2010.5</pub-id>
<pub-id pub-id-type="pmid">20360767</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-20-03358">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Poisson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The I-TASSER Suite: Protein structure and function prediction</article-title>
<source/>Nat. Methods
          <year>2015</year>
<volume>12</volume>
<fpage>7</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.3213</pub-id>
<pub-id pub-id-type="pmid">25549265</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-20-03358">
<label>102.</label>
<element-citation publication-type="journal">
<article-title>Wu S, Zhang Y: LOMETS: A local meta-threading-server for protein structure prediction</article-title>
<source/>Nucleic Acids Res.
          <year>2007</year>
<volume>35</volume>
<fpage>3375</fpage>
<lpage>3382</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkm251</pub-id>
<pub-id pub-id-type="pmid">17478507</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-20-03358">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rual</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Venkatesan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hirozane-Kishikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dricot</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Berriz</surname>
<given-names>G.F.</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>F.D.</given-names>
</name>
<name>
<surname>Dreze</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ayivi-Guedehoussou</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Towards a proteome-scale map of the human protein-protein interaction network</article-title>
<source/>Nature
          <year>2005</year>
<volume>437</volume>
<fpage>1173</fpage>
<lpage>1178</lpage>
<pub-id pub-id-type="doi">10.1038/nature04209</pub-id>
<pub-id pub-id-type="pmid">16189514</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-20-03358">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Finger</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Hayamizu</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>McCright</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Berghout</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Corbani</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Forthofer</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>The mouse gene expression database (GXD): 2014 update</article-title>
<source/>Nucleic Acids Res.
          <year>2014</year>
<volume>42</volume>
<fpage>D818</fpage>
<lpage>D824</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkt954</pub-id>
<pub-id pub-id-type="pmid">24163257</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-20-03358">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandal</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Haney</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Parikshak</surname>
<given-names>N.N.</given-names>
</name>
<name>
<surname>Leppa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ramaswami</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hartl</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schork</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Appadurai</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Buil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Werge</surname>
<given-names>T.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap</article-title>
<source/>Science
          <year>2018</year>
<volume>359</volume>
<fpage>693</fpage>
<lpage>697</lpage>
<pub-id pub-id-type="doi">10.1126/science.aad6469</pub-id>
<pub-id pub-id-type="pmid">29439242</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-20-03358">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaaf</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Sabo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Muzny</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hawes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Akbar</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Varghese</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Boerwinkle</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders</article-title>
<source/>Hum. Mol. Genet.
          <year>2011</year>
<volume>20</volume>
<fpage>3366</fpage>
<lpage>3375</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr243</pub-id>
<pub-id pub-id-type="pmid">21624971</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-20-03358">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model</article-title>
<source/>Mol. Autism
          <year>2018</year>
<volume>9</volume>
<fpage>64</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-018-0247-z</pub-id>
<pub-id pub-id-type="pmid">30564305</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-20-03358-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Graphic representation of the secondary structure of <italic>SYTL4</italic> gene indicating the location of Rab binding domain, ring domain, C2 domains, and the location of arginine at amino acid position 279.</p>
</caption>
<graphic xlink:href="ijms-20-03358-g001"></graphic>
</fig>
<fig id="ijms-20-03358-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>The native SYTL4 protein structure contains the C2 domains, ring domain, and an apparent salt bridge between arginine (R279) and aspartic acid (D60) as noted in (<bold>A</bold>). Arginine 279 (side chain in red) is part of a large extended loop conformation that appears to be stabilized by an apparent salt bridge formed between it and Asp60 (side chain in Salmon) in the ring domain. The distance (3.116Å) calculated between the Arg guanidinium nitrogen and Asp carboxyl oxygen is well within the threshold distance observed for salt bridges in a comprehensive survey of crystal structures as noted in (<bold>B</bold>).</p>
</caption>
<graphic xlink:href="ijms-20-03358-g002"></graphic>
</fig>
<fig id="ijms-20-03358-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Effect of the R[Arg]⇒C[Cys] amino acid change at 279 on the structure of SYTL4 Proteins. Theoretical 3D structures of native and R279C SYTL4. Hierarchical protein structural modeling of both native (<bold>A</bold>) and R279C (<bold>B</bold>) SYTL4 proteins were carried out using I-TASSER. Three X-ray crystal structures of human Synaptotagmin C2 domains (Protein Data Bank ID: 2R83, 4P42 and 3HN8) among the top 10 templates used for both SYTL4 forms. Native SYTL4 (grey ribbon trace) and R279C variant (gold ribbon trace) are shown with C2(1), C2(2) and ring domains rendered as light green, dark green and cyan traces, respectively, in Panels (<bold>A</bold>,<bold>B</bold>). Panel (<bold>A</bold>): SYTL4 native protein structure indicating the C2 domains, ring domain, and an apparent salt bridge between arginine (R279) and aspartic acid (D60). Shown magnified in the native SYTL4 structure is the apparent salt bridge formed between D60 and R279. Panel (<bold>B</bold>): SYTL4 R279C variant (gold ribbon trace) shows significant displacement of both the 279 amino acid site (salmon ribbon trace) and ring domains of native (cyan ribbon trace). Panel (<bold>C</bold>): An overlay of native <bold>(A)</bold> and R279C (<bold>B</bold>) SYTL4 structures demonstrates relatively good alignment for the C terminal C2 domains and confirms the significant displacement of both the 279 amino acid site (salmon ribbon trace) and ring domains of native (cyan ribbon trace) SYTL4.</p>
</caption>
<graphic xlink:href="ijms-20-03358-g003"></graphic>
</fig>
<fig id="ijms-20-03358-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>STRING- Protein-Protein Interaction Network of SYTL4. [<uri xlink:href="https://version11.string-db.org/cgi/network.pl?taskId=f7upTuHlbV0A">https://version11.string-db.org/cgi/network.pl?taskId=f7upTuHlbV0A</uri>]. SYTL4- Interacting ASD Genes; <italic>SYTL4</italic>: Synaptotagmin-like protein 4; modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca (2+)-independent manner; synaptotagmin-like tandem C2 proteins. STXBP1: Syntaxin-binding protein 1; may participate in the regulation of synaptic vesicle docking and fusion. Essential for neurotransmission and binds syntaxin, a component of the synaptic vesicle fusion machinery (Score: 0.746). STX1A: Syntaxin-1A; plays a role in hormone and neurotransmitter exocytosis. Potentially involved in docking of synaptic vesicles at presynaptic active zones (Score: 0.805). SNAP25: Synaptosomal-associated protein 25; t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems (Score: 0.551).</p>
</caption>
<graphic xlink:href="ijms-20-03358-g004"></graphic>
</fig>
<fig id="ijms-20-03358-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>SYTL4 amino acids sequence data for the “canonical” form and its truncated isoform 2, both encompassing the alternating exon 9 with the missense mutation resulting in R[Arg]⇒C[Cys] at 279: Amino acid sequences that are highlighted in blue are the first 335 amino acids which are common to both the full length ‘canonical’ sequence of the SYTL4 protein and its truncated isoform 2, both containing the alternating exon 9 Glu(E) 270–Met(M) 304, highlighted in yellow with the R[Arg]⇒C[Cys] at 279. The location of native arginine residue (at 279) in-between two Serine(S) amino acid residues at 274 and 289 positions (which have been shown to undergo post-translational phosphorylation) is underlined. The RAB-Binding Domain (comprised of amino acids 4 through 122) is also indicated with underline, within which lies D[Asp] at position 60 and takes part in the apparent salt bridge formation with R[Arg] at 279 in the native protein configuration. The presence of mutant C[Cys] at 279 leads to the formation of an extended beta-pleated sheet therein instead (as seen in <xref ref-type="fig" rid="ijms-20-03358-f003">Figure 3</xref>A,B).</p>
</caption>
<graphic xlink:href="ijms-20-03358-g005"></graphic>
</fig>
<fig id="ijms-20-03358-f006" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<p>(<bold>A</bold>). Graphic representation of TMEM187 protein indicating the location of Q236H amino acid variation beyond the last (6th) transmembrane helical domain (191-210aa), at the near terminal end of the <italic>Pfam</italic> domain (8-245aa) (<uri xlink:href="https://pfam.xfam.org/family/tmem187">https://pfam.xfam.org/family/tmem187</uri>; TMEM187 (PF15100)). (<bold>B</bold>). Theoretical partial 3D protein structure of the encoded multi-pass transmembrane protein targeting the 15-200aa region (<uri xlink:href="https://modbase.compbio.ucsf.edu/">https://modbase.compbio.ucsf.edu/</uri>), excluding the Q236H amino acid variant near the terminal end region of the protein which is represented by multiple sequence alignments and hidden Markov models preventing comparative structural analysis of the variant harboring region.</p>
</caption>
<graphic xlink:href="ijms-20-03358-g006"></graphic>
</fig>
<fig id="ijms-20-03358-f007" orientation="portrait" position="float">
<label>Figure 7</label>
<caption>
<p>STRING-Protein–Protein Interactions of TMEM187. (<uri xlink:href="https://string-db.org/network/9606.ENSP00000358999">https://string-db.org/network/9606.ENSP00000358999</uri>). TMEM187- Interacting ASD Genes: HCFC1: <italic>Host cell factor 1</italic>: Involved in control of the cell cycle; Coactivator for EGR2 and GABP2 (Score: 0.747); TMLHE: Trimethyllysine dioxygenase, mitochondrial: Converts trimethyllysine (TML) into Hydroxytrimethyllysine (HTML). (Score: 0.657); MECP2: Methyl-CpG-binding protein 2: Chromosomal protein that binds to methylated DNA; Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A (Score: 0.555); GPHN: Gephyrin: Microtubule-associated protein involved in membrane protein-cytoskeleton interactions (Score: 0.531).</p>
</caption>
<graphic xlink:href="ijms-20-03358-g007"></graphic>
</fig>
<table-wrap id="ijms-20-03358-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-03358-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>SYTL4 Molecular Pathways and Associated Diseases.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pathway ID</th>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pathway Description</th>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Count in Gene Set</th>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">False Discovery Rate</th>
<th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Functional Description</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4721</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Synaptic vesicle cycle</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0161</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Communication between neurons is mediated by the release of neurotransmitter from synaptic vesicles (SVs). At the nerve terminal, SVs cycle through repetitive episodes of exocytosis and endocytosis. SVs are filled with neurotransmitters by active transport. DISEASES: Early infantile epileptic encephalopathy; Centronuclear myopathy; Episodic ataxias; Familial or sporadic hemiplegic migraine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4911</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Insulin secretion</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0161</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Insulin secretion is regulated by several hormones and neurotransmitters. Peptide hormones, such as glucagon-like peptide 1 (GLP-1), increase cAMP levels and thereby potentiate insulin secretion via the combined action of PKA and Epac2.<break></break>Acetylcholine (Ach), a major parasympathetic neurotransmitter. DISEASES: Type II diabetes mellitus; Defects in the degradation of ganglioside.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4152</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AMPK signaling pathway</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0325</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4130</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SNARE interactions </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0432</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SNARE proteins (an acronym derived from “SNAP (Soluble NSF Attachment Protein) Receptor”). The primary role of SNARE proteins is to mediate vesicle fusion, that is, the fusion of vesicles with their target membrane-bound compartments. The best studied SNAREs are those that mediate docking of synaptic vesicles with the presynaptic membrane in neurons.<break></break>DISEASES: Pseudohypoparathyroidism and Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome; CEDNIK syndrome.</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-20-03358-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-03358-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>SYTL4- Network: Biological Processes</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pathway ID</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pathway Description</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Count in Gene Set</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">False Discovery Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0048489</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">synaptic vesicle transport</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.14 × 10<sup>−9</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0097479</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">synaptic vesicle localization</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.14 × 10<sup>−9</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0016079</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">synaptic vesicle exocytosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.79 × 10<sup>−9</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0016082</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">synaptic vesicle priming</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.14 × 10<sup>−7</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0031629</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">synaptic vesicle fusion to presynaptic membrane</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5.45 × 10<sup>−7</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0007269</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">neurotransmitter secretion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.06 × 10<sup>−6</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0048167</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">regulation of synaptic plasticity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.000171</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0032482</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RAB protein signal transduction</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.000701</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0031630</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">regulation of synaptic vesicle fusion to presynaptic membrane</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.00156</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0014047</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">glutamate secretion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.00165</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0007268</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">synaptic transmission</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0115</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0023051</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">regulation of signaling</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0211</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0050803</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">regulation of synapse structure or activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0249</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0050804</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">modulation of synaptic transmission</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0356</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0007274</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">neuromuscular synaptic transmission</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0385</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0065008</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">regulation of biological quality</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0389</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0007409</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">axonogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.0393</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-20-03358-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-03358-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Molecular Function (GO)</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pathway ID</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pathway Description</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Count in Gene Set</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">False Discovery Rate</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Functional Description and Associated Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0019905; GO:0017075</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Syntaxin binding</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5.46 × 10<sup>−7</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Syntaxin binding is essential for neurotransmission: syntaxin is a component of the synaptic vesicle fusion machinery.<break></break>Mutations in Syntaxin binding protein 1 (STXBP1) have been associated with infantile-epileptic encephalopathy-4 [<xref ref-type="bibr" rid="B28-ijms-20-03358">28</xref>].</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0005484</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SNAP receptor activity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.000161</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SNAPRE activity also regulates neurotransmitter release to ensure vesicle-to-target specificity (SNAP receptors implicated in vesicle targeting and fusion [<xref ref-type="bibr" rid="B29-ijms-20-03358">29</xref>].</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GO:0019003</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GDP binding</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.019</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The trimeric-G-protein (GTP binding proteins) play a pivotal role in the signal transduction pathways for numerous hormones and neurotransmitters [<xref ref-type="bibr" rid="B30-ijms-20-03358">30</xref>].</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-20-03358-t004" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-03358-t004_Table 4</object-id>
<label>Table 4</label>
<caption>
<p>Showing the Five Autism Predictive Human Serum MicroRNAs with Predicted Interaction with Mouse <italic>Sytl4</italic> Gene.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Sytl4-miR=ASD-miR</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Mouse Sytl4- miRs: Predicted Interactions with ASD &amp; Schizophrenia- Associated miRs</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Validation</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR93</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR93</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dysregulated in superior temporal gyrus of ASD</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stomova, et al., 2015 [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR103-1; miR103-2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR103</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dysregulated in superior temporal gyrus of ASD</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stomova, et al., 2015 [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR106b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR106b-5p (miR106b) *</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Upregulated in ASD-serum; differentially expressed in ASD cerebellar cortex</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] and Abu-Elneel K, et al., 2008 [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR106b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schizophrenia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered expression (serum/cortical)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] and Shi, et al., 2012 [<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>], Beveridge and Cairns, 2012 [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>].</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR130a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR130a-3p (miR130a) **</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Good predictive power for ASD- serum</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-130a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schizophrenia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered expression (serum/cortical)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]; Shi, et al., 2012 [<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>], Beveridge and Cairns, 2012 [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR132</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR132</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dysregulated in superior temporal gyrus of ASD</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stomova, et al., 2015 [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"> miR181b-1 (miR181b) ***</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR181b-2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR181b-5p (miR181b/b1) ***</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Good predictive power for ASD in serum; differentially expressed in ASD cerebellar cortex</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al. 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]. Abu-Elneel K, et al. 2008 [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>]. Ghahramani Seno, et al., 2011 [<xref ref-type="bibr" rid="B36-ijms-20-03358">36</xref>].</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR181b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schizophrenia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered expression (serum/cortical)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]; Shi, et al., 2012 [<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>], Beveridge and Cairns, 2012 [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>].</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR320</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR320a (miR320) ****</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Good predictive power for ASD in serum</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR320</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dysregulated in superior temporal gyrus of ASD</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stomova, et al., 2015 [<xref ref-type="bibr" rid="B37-ijms-20-03358">37</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR320</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Differentially expressed in ASD cerebellar cortex</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abu-Elneel K, et al. 2008 [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR328</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sytl4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Predicted</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MGI:1351606c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR328</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Down regulated in serum; differentially expressed in ASD cerebellar cortex</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] and Abu-Elneel K, et al., 2008 [<xref ref-type="bibr" rid="B35-ijms-20-03358">35</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR328</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schizophrenia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered expression (serum/cortical)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vasu, et al., 2014 [<xref ref-type="bibr" rid="B34-ijms-20-03358">34</xref>] and Shi, et al., 2012 [<xref ref-type="bibr" rid="B33-ijms-20-03358">33</xref>]; Beveridge and Cairns, 2012 [<xref ref-type="bibr" rid="B32-ijms-20-03358">32</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>* <uri xlink:href="http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000407">http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000407</uri>; ** <uri xlink:href="http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000156">http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000156</uri>; *** <uri xlink:href="http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0000673">http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0000673</uri>; **** <uri xlink:href="http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000542">http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000542</uri>; C. <uri xlink:href="http://www.informatics.jax.org/interaction/explorer?markerIDs=MGI:1351606">http://www.informatics.jax.org/interaction/explorer?markerIDs=MGI:1351606</uri>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>